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Background:  The human immunodeficiency virus-1 (HIV-1) causes cognitive impairment 
in up to 50% of HIV-infected individuals.  High prevalence rates of HIV-associated 
neurocognitive disorders (HAND) have been reported in South Africa.  Systemic 
inflammation associated with HIV-infection may enhance neuroinflammation, and 
ultimately neurodegeneration, through signalling from the periphery to the brain.  In the 
South African setting, opportunistic infections remain common.  South Africans are 
predominantly infected with clade C of HIV-1 for which we have limited information about 
its neurological complications.  Indigenous South Africans have a high frequency of the ε4 
allele of the apolipoprotein E gene (APOE) and APOE ε4 has been investigated as a risk 
factor for HAND.  A study of the relationships between systemic infection, APOE genotype 
and cognitive impairment is therefore relevant in our setting. 
 
Aims:  This study aimed to define the role of systemic inflammation in the pathogenesis of 
HAND.  We hypothesised that high levels of pro-inflammatory cytokines in the blood would 
be associated with more severe cognitive impairment.  Conversely, better cognition would 
be associated with high levels of anti-inflammatory cytokines.  We also hypothesised that 
participants with an initial pro-inflammatory cytokine profile would respond better to 
combination antiretroviral therapy (cART) in terms of cognitive function.  Furthermore, the 
presence of the ε4 allele would be associated with more inflammation as well as greater 
cognitive impairment prior to cART.  
 
Methods:  HIV-positive, cART-naïve participants were recruited from primary care clinics 
in the Western Cape.  Neuropsychological test batteries were used to derive global deficit 
scores (GDS) at baseline and after at least 9 months of cART.  APOE genotyping and 
measurements of systemic pro- and anti-inflammatory cytokines (IL-1β, TNF-α, IL-10, and 
TGF-β) were performed on samples collected at baseline.  The GDS, cytokine levels and 
APOE data were used in correlation analyses. 
 
Results:  114 participants were assessed at baseline and 40 at follow-up.  No correlation 
between systemic cytokine levels and cognitive impairment was found.  The ε4 allelic 
frequency was high in this sample, but was not associated with worse cognitive 
impairment.  IL-10 levels tended to be higher and TGF-β levels tended to be lower in ε4 
carriers.  TGF-β concentrations were significantly higher in ε3 carriers compared with non-
ε3 carriers.  Baseline cytokine levels did not predict cognitive response to cART. 
 
Conclusions:  This study of young HIV-infected people confirmed the high prevalence of 
the ε4 allele in our region.  While ε4 was not associated with worse cognitive impairment, 
this association may only be seen in older HIV-infected individuals.  The ε3 allele was 
associated with higher anti-inflammatory cytokine concentrations and may, therefore, 
confer neuroprotection in HIV-infected patients.  Measurements of systemic cytokines 
appear to have limited value as surrogate markers of neuroinflammation – cerebrospinal 
fluid measurements may be better.  More sophisticated statistical models may be required 
to relate multiple cytokine measurements to cognitive function. 
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CHAPTER 1: INTRODUCTION 
 
1.1 General background and rationale of the study 
 
The human immunodeficiency virus type 1 (HIV-1) is a lentivirus that belongs to the family 
of retroviruses (Cullen 1991; Weiss et al. 1985).  HIV-1 was first identified in 1983, and it 
was soon discovered to be morphologically and genetically related to other lentiviruses, 
known to cause multi-organ disease and death (Gonda et al. 1985; Barre-Sinoussi et al. 
1983). 
 
HIV-1 predominantly infects cluster of differentiation type four (CD4+) T lymphocytes in the 
peripheral blood but also infects other cells of the immune system such as monocytes or 
macrophages (Ellis et al. 2009; Rosenberg and Fauci 1989; McElrath et al. 1989). 
 
The central nervous system (CNS) is susceptible to infection by retroviruses and the brain 
is the most frequently infected organ following HIV-associated lung pathology (Masliah et 
al. 2000; Clements and Zink 1996).  HIV-1 is very often associated with debilitating CNS 
disorders (Grant et al. 2005; McArthur et al. 2005). 
 
HIV-1 enters the CNS as a passenger within infected monocytes as they cross the blood-
brain barrier (BBB).  Once inside the brain these monocytes differentiate into 
macrophages where an HIV reservoir is created (González-Scarano and Martin-Garcia 
2005; Rosenberg and Fauci 1989; Koenig et al. 1986; Wiley et al. 1986).  It is likely that 
HIV-1 infection of the CNS becomes established early after systemic viral infection, and 
possibly even before seroconversion occurs (Davis et al. 1992; Resnick et al. 1988). 
 
Upon entering the brain, HIV-1 initiates an inflammatory response (neuroinflammation) by 
directly activating brain macrophages, microglia, and astrocytes, with the resultant 
production of excessive neurotoxic pro-inflammatory factors.  This immune activation 
ultimately leads to neuronal damage and loss (neurodegeneration).  The latter results in 
cognitive impairment (Hazleton et al. 2010; Wang et al. 2006).  HIV-associated 
inflammation, characterized by peripheral monocyte infiltration with activation of brain 
macrophages and microglia, is therefore believed to play a central role in CNS disease  
(Deeks 2011; Wang et al. 2006).   
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The brain is however not an “immune-privileged” organ as was previously thought and it 
does also respond to systemic inflammatory stimuli and immune responses (Wärnberg et 
al. 2009).  CNS HIV-1 infection forms an important component of systemic infection and 
the level of systemic immune activation modulates HIV infection in the CNS (Sinclair et al. 
2008).  A possible trigger of chronic systemic immune activation in HIV-1 infection is 
elevation of a circulating endotoxin, bacterial lipopolysaccharide (LPS).  These elevated 
levels of LPS are a consequence of translocation of bacterial products from a leaky gut 
associated with HIV infection (Brenchley et al. 2006b).  LPS triggers monocyte activation, 
and activated monocytes play a key role in the pathogenesis of HIV-associated cognitive 
impairment (Ancuta et al. 2008; González-Scarano and Martin-Garcia 2005; McArthur et 
al. 2003; Kaul et al. 2001).  The numbers of circulating activated monocytes have been 
clearly associated with the development of HIV dementia (Gartner 2000; Pulliam et al. 
1997; Tyor et al. 1992).  
 
HIV infection leads to increased numbers of circulating monocytes from the bone marrow, 
and also increased levels of monocytes that circulate in an activated state (Fischer-Smith 
and Rappaport 2005; Thieblemont et al. 1995).  The elevated levels of LPS that lead to the 
immune activated state associated with HIV-infection also cause increased levels of 
circulating cytokines (Douek 2007; Brenchley et al. 2006b). The BBB becomes more leaky 
and therefore more HIV-infected monocytes can enter the brain (Wang et al. 2008; Zhou 
et al. 2006).  It thus follows that there is an association between the systemic inflammatory 
response and the numbers of activated macrophages and microglia in the CNS, neuronal 
damage and cognitive dysfunction (Glass et al. 1995).  Numerous studies have recognized 
systemic inflammation as a key driver of HIV-1 pathogenesis, both in the periphery and in 
the CNS (Deeks 2009; Brenchley et al. 2006b).  We can therefore postulate that repeated 
or chronic systemic infections and inflammation – as is common in HIV disease – may 
drive and enhance the process of neuroinflammation, and ultimately neurodegeneration, 
through signalling from the peripheral blood to the CNS. 
 
Neurodegeneration in HIV-infected individuals results in the clinical syndromes of the HIV-
associated neurocognitive disorders (HAND).  These neurocognitive disorders can range 
in severity from slight deficits to debilitating dementia (Ellis et al. 2009).  The classification 
of HAND comprises three categories based on standardized diagnostic procedures: 
asymptomatic neurocognitive impairment (ANI), HIV-associated mild neurocognitive 
disorder (MND), and HIV-associated dementia (HAD).  ANI and MND are characterized by 
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mild cognitive impairment but with MND there is also mild interference with everyday 
functioning.  HAD (formerly known as AIDS dementia complex) is characterized by severe 
cognitive impairment causing marked interference with activities of daily living (ADLs).   
The research criteria further require that the impairment is not due to delirium and cannot 
be fully explained by comorbid conditions (Antinori et al. 2007). 
 
During the early stages of HAND, clinical symptoms may be absent (ANI) or subtle (MND) 
but they can progress in severity to a disorder of cognitive, behavioural and motor 
dysfunction (Jannsen et al. 1991; Navia et al. 1986).  HAD is characterized by deficits in 
learning, motor coordination, verbal fluency, memory, attention and processing speed  
(Cysique et al. 2006). 
 
The ε4 allele of the apolipoprotein E gene (APOE) has been investigated as a risk factor 
for the development of HAND. The results are, however, controversial with some studies 
identifying ε4 as a risk factor for developing HAD (Spector et al. 2010; Corder et al. 1998) 
while others found no association between the presence of ε4 and an altered rate of 
progression to HAD (Burt et al. 2008; Dunlop et al. 1997).  It is possible that a correlation 
between APOE ε4 and HAD is age-dependent (Valcour et al. 2004a).  The ε4 allele is less 
effective than ε3 at down-regulating the brain inflammatory response.  It has been 
associated with an increased expression of pro-inflammatory cytokines in vitro, and also 
with the presence of an increased pro-inflammatory immune response in vivo - both 
peripherally and centrally (Vitek et al. 2009; Harry et al. 2000).  APOE ε4 has been shown 
to accelerate HIV disease progression and increase susceptibility to infection in vitro (Burt 
et al. 2008). 
 
As per reports from the developed world (e.g. America and Europe), the widespread use 
of combination antiretroviral therapy (cART) has significantly altered the nature of HAND, 
specifically decreasing the incidence of HAD (McArthur 2004; Sacktor et al. 2002). The 
less severe forms of HAND, however, remain common.  In general, the initiation of cART 
improves neuropsychological function, but this improvement is neither full nor universal 
(Joska et al. 2010c).  The early cognitive response following cART initiation is likely to be 
associated with rapid suppression of acute neuroinflammation as well as immune recovery 
and lower viral loads in both the systemic circulation and in the CNS (Heaton et al. 2010; 
Liner II et al. 2008; Gendelman et al. 1998). 
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1.1 Problem statement 
 
HIV-1 is an important global health concern and South Africa has the highest number of 
people living with HIV/AIDS (PLWHA) according to the WHO/UNAIDS report of 2010 (Joint 
United Nations Programme on HIV/AIDS 2010).   
 
HIV-1 infection worldwide is classified into subtypes (clades) based on the genetic 
similarity of the viral strain and the geographic regions where they predominate (Ellis et al. 
2009).  There are at least 10 different genetic HIV-1 subtypes, labelled A to J, responsible 
for the AIDS pandemic.  Sub-Saharan Africa is the region most affected by the HIV 
epidemic and here HIV-1 clade C infection is most common, accounting for around 50% of 
infections worldwide.  The majority of HIV research has, however, been conducted in 
Caucasian populations in the developed world – Europe, Australia and the Americas – 
where HIV infection is almost exclusively due to subtype B.  These research findings are 
responsible for much of our current understanding of the disease progression of HIV-1 and 
may not be generalizable to HIV clades and human populations in Sub-Saharan Africa or 
other developing countries (Ellis et al. 2009; McCutchan 2006; Kanki et al. 1999). 
 
HAND affects around 50% of PLWHA (Heaton et al. 2010; Grant 2008; McArthur et al. 
1993).  The first detailed HAND study in South Africa was performed at primary care 
clinics in Cape Town and high prevalence rates for HAD (25.3%) and MND (42.4%) were 
reported.  These rates were in keeping with other studies from the developing world such 
as Uganda and India (Joska et al. 2010d).  It is clear that HAND and, especially, HAD 
remains prevalent in South Africa despite the use of cART. 
 
African populations have a higher frequency of the ε4 allele of the APOE gene (Burt et al. 
2008; Eichner et al. 2002; Kamboh et al. 1989) and up to 37% of native Africans, such as 
the Khoi San, who live in Southern Africa, are carriers of the ε4 allele (Sandholzer et al. 
1995).  A high frequency of the ε4 variant was also found among IsiXhosa speakers in 
South Africa, and this was similar to reports of other African populations (Joska et al. 
2010a). 
 
The use of cART leads to immune recovery and a reduction in the occurrence of 
opportunistic infections in HIV-infected people.  However, in sub-Saharan Africa, 
opportunistic infections such as tuberculosis, cryptococcal disease, and syphilis remain 
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common (Sacktor et al. 2006).  This is also the case in our South African setting where 
access to antiretroviral therapy (ART) is often delayed and occurs late in the course of the 
disease (Joska et al. 2010d).   
 
The pathogenesis of HAND is not clearly understood but it is believed that HIV enters the 
CNS very early after infection, resulting in the activation of the macrophages and microglia 
within the brain.  This, in turn, initiates a neuroinflammatory response.  There is also 
mounting evidence that links systemic inflammation with neuroinflammation.  We can 
postulate that repeated systemic infections and inflammation, as commonly occur in HIV 
disease, may drive and enhance the process of neuroinflammation.  The latter ultimately 
leads to neurodegeneration.   
 
In South Africa HIV-1 clade C is responsible for most of the burden of HIV infection.  There 
are still limited data available about the neurological complications of clade C, as most 
studies have been done in clade B regions. The frequency of the APOE ε4 allele is high in 
indigenous southern African populations compared with studies in North America and 
Europe (Sandholzer et al. 1995).  A study of the relationship between systemic infection, 
APOE genotype and cognitive impairment is therefore both biologically important and 
clinically relevant in our setting.   
 
We hope to provide information about risk or associative factors that might help us to 
understand why some people with HIV develop cognitive impairment while others do not.  
This might also help with the early identification of patients at risk for developing HIV-
associated dementia and assist us in identifying patients expected to have a poorer 
neurocognitive response to cART.  We hypothesize that a predominantly pro-inflammatory 
cytokine profile in the peripheral blood of HIV-positive participants, who are not yet on 
cART (cART-naïve), will correlate with more severe cognitive impairment.  Conversely, 
better cognition will be associated with a predominantly anti-inflammatory cytokine profile.  
Participants with an initial pro-inflammatory cytokine profile will respond better to cART in 
terms of cognitive function.  The presence of the ε4 allele of APOE will be associated with 





1.2 Overview of methodology 
 
This retrospective, observational study had two components: a cross-sectional baseline 
analysis correlating various factors with cognitive function, and a longitudinal part.  Ethical 
approval was obtained from the University of Cape Town/Groote Schuur Hospital Human 
Human Research Ethics Committee (HREC)(No. REC 263/2007).  This study formed part 
of an existing research project that recruited 167 young adult, HIV-positive, cART-naïve 
participants from primary care ARV clinics in Cape Town, South Africa. 
 
The cross-sectional component of my project involved a sample of 114 of the original 167 
participants who completed baseline assessments.  Pro-and anti-inflammatory cytokines 
were measured in the stored serum samples.  Global deficit scores (GDS) (Carey et al. 
2004a; Heaton et al. 1995) were calculated from the neurocognitive tests performed at 
initial and follow-up visits.  These scores were correlated with inflammatory cytokines as 
well as with the data from APOE genotyping performed in the existing research project.  
 
The longitudinal data of 40 participants who returned for follow-up assessments, after at 
least 9 months on cART, were analysed.  The GDS at follow-up was compared with the 
GDS at baseline to determine if cognitive function improved, worsened or was maintained 
after starting ART. 
 
All data, including the results of the cytokine assays, were recorded on a Microsoft Excel 
spread sheet.  Statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS) version 21.  The significance level was set at α = 0.05. 
 
In the next chapter I shall review the literature on HIV neuropathogenesis, inflammation 










This chapter will explore the pathogenesis of HAND with a specific focus on the 
neuropathogenic role of systemic inflammation and infection.  The chapter will start with 
how HIV-1 infects the CNS and then follow with a detailed discussion of HAND with 
emphasis on inflammation and inflammatory cytokines.  Risk or associative factors of 
HAND will also be reviewed, with viral clade and apolipoprotein E discussed in detail 
under separate headings.  The chapter will conclude with a summary of the previous 
research and how it relates to this study. 
 
2.2 HIV-1 infection in the CNS 
 
HIV-1 primarily infects the immune system by binding to CD4+ T lymphocytes in the 
peripheral blood.  It is the gradual depletion of the CD4+ T cell population that is 
responsible for the progressively severe immunosuppression that characterizes HIV 
infection (Schnittman et al. 1989; McDougal et al. 1985).  HIV-1 has also been shown to 
infect another class of CD4+ cells, both in vitro and in vivo, namely the 
monocyte/macrophage cells (Rosenberg and Fauci 1989).  The CNS is susceptible to 
infection by retroviruses and particularly by members of the lentivirus family (Clements and 
Zink 1996).  A large number of individuals infected by HIV-1 develop debilitating 
neurological complications (Joska et al. 2011).  It is likely that infection of the CNS 
becomes established early, possibly even before seroconversion occurs.  However, it is 
uncertain if neurological damage begins at this stage or only occurs later after systemic 
immunosuppression has developed (McArthur et al. 2010).  In the brain HIV is 
predominantly found in the macrophages or microglia.  Infected monocytes from the 
periphery cross the blood-brain barrier and differentiate into macrophages.  In this way, 
HIV establishes a reservoir within these perivascular macrophages (González-Scarano 
and Martin-Garcia 2005; Rosenberg and Fauci 1989).  Chronic HIV-1 infection results in 
neurodegenerative disease (Shapsak et al. 2011).  Neurodegeneration is, however, not 
caused by direct infection of neurones, but rather through the infection of macrophages 
and the resultant inflammatory activation that indirectly cause neuronal damage.  
Macrophages, therefore, are thought to play a pivotal role in the neuropathogenesis of 
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HIV-infection and the resulting clinical syndromes of the HIV-associated neurocognitive 




Figure 2.1 HIV-associated neurocognitive disorders (HAND) 
 (McArthur et al. 2010) 
 
2.3 HIV-associated neurocognitive disorders 
 
2.3.1 Neuropathogenesis of HAND 
 
A. Neuroinvasion (Figure 2.2) 
 
HIV-1 is known to enter the CNS within days of primary infection (An et al. 1999; Davis et 
al. 1992).  Haase and colleagues proposed that HIV and other lentiviruses enter the CNS 
as passengers in cells that traffic to the brain.  The monocyte is a type of CD4+ cell in the 
peripheral circulation that is infected by HIV.  The monocyte conceals the virus genome 
and carries it without detection by the immune system to different sites in the body (Haase 
1986; Peluso et al. 1985).  HIV is able to cross the BBB by this “Trojan Horse” method (a), 
which remains the most widely accepted model of HIV neuroinvasion (Liu et al. 2002).  
Monocytes traffic to the brain to replenish the perivascular macrophage population  
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(González-Scarano and Martin-Garcia 2005; Williams et al. 2001b; Kaul et al. 2001).  
Once inside the brain they differentiate into macrophages (b) and HIV is believed to 
establish a reservoir within this perivascular macrophage population (Rosenberg and 
Fauci 1989; Koenig et al. 1986).  Perivascular macrophages, situated around CNS blood 
vessels, are derived from the bone marrow and are continually replaced by monocytes 
from the circulation.  This normal turnover of perivascular cells provides an “open door” for 
HIV to access the CNS (González-Scarano and Martin-Garcia 2005; Williams et al. 2001b) 
Chemokines are important mediators of the transmigration of monocytes across the BBB 
and also direct the movement of resident microglia and macrophages.  Chemokine (C-C 
motif) ligand 2 (CCL2) is the most potent chemo-attractant chemokine and plays a key role 
in the infiltration of HIV-infected monocytes into the CNS and the neuropathogenesis of 




Figure 2.2 HIV neuroinvasion and multinucleated-giant cell formation 
(González-Scarano and Martin-Garcia 2005) 
 
Several cell types in the perivascular region of the brain – mainly astrocytes, perivascular 
macrophages, and microglia – come into direct contact with HIV-infected monocytes from 
the periphery.  Of these, perivascular macrophages and microglia (macrophages of brain 
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parenchyma) are the most important as they become productively infected with HIV, and 
are likely to mediate the neurodegeneration seen in patients with HAD (González-Scarano 
and Martin-Garcia 2005; Williams et al. 2001a). Infected CNS cells express HIV-envelope 
glycoproteins that mediate cell-to-cell fusion with cells that express both CD4 and HIV co-
receptor.  In the brain this fusion involves infected macrophages and microglia to form 
multinucleated giant cells (c) that can also produce virus before they die.  Multinucleated 
giant cells are reported to be the hallmark of HIV neuropathology (González-Scarano and 
Martin-Garcia 2005).  HIV-1 might also enter the brain in infected CD4 T+ cells, but it is still 
unclear whether these cells contribute to the pool of replicating virus in the brain 
(González-Scarano and Martin-Garcia 2005).  HIV infection of astrocytes is restricted and 
not productive (e), as they do not contribute to viral replication (Wang et al. 2006). There is 
no evidence of productive infection of neurones in vivo (Sharpless et al. 1992).  However, 
Torres-Muñez and colleagues detected HIV-1 deoxyribonucleic acid (DNA) sequences in 
brain neurones of a small study sample in vivo (Torres-Muñoz et al. 2001).  Whether this 
neuronal infection could contribute to neuronal injury and death remains uncertain.  
Numerous studies have, however, been published that support other mechanisms that 
mediate the neuropathology of HIV. 
 
In the following section I will elaborate on these pathogenetic mechanisms by discussing 
the direct and indirect models of neurodegeneration.  
 
B. Mechanisms of neurodegeneration 
 
The exact pathogenesis underlying HIV-1 associated CNS dysfunction remains unclear.  
The number of HIV-infected cells does not always correlate with the severity and course of 
clinical disease.  This fact supports mechanisms other than direct viral toxicity as the 
cause of CNS damage (Schouten et al. 2011).  Shortly after HIV-1 enters the brain and 
settles in the perivascular macrophages and microglia, these cells become activated and a 
neuroinflammatory response results.  The latter eventually leads to the cognitive 
impairment observed in some patients (Schouten et al. 2011; Hazleton et al. 2010).  There 
are at present two main theories of HIV-associated neurodegeneration.  Disruption of 
normal neurological functions can either be caused by a direct mechanism or by an 
indirect or “bystander” effect.  Both these models require initial productive HIV-infection of 
perivascular macrophages and microglia, and are not mutually exclusive.  They might well 
coexist.  Most of the available evidence does, however, support the bystander model as 
 11 
the predominant mechanism of neurodegeneration in HAND (González-Scarano and 
Martin-Garcia 2005).  Refer to Figure 2.3: 
 
In the direct injury hypothesis, infected cells release HIV proteins, glycoprotein 120 
(gp120), transcriptional transactivator (Tat) or viral protein R (vpR) (a).  The interaction of 
these viral proteins and neurones causes damage or injury to the latter (Kaul et al. 2005; 
González-Scarano and Martin-Garcia 2005).  It remains uncertain, however, whether the 
concentrations of viral proteins that are present in the CNS are high enough to mimic the 
effects observed in in vitro experiments (Klasse and Moore 2004; Albright et al. 2003). 
Toxic viral proteins may work in conjunction with factors released from microglia and 
astrocytes to promote neurodegeneration.  
 
In the indirect, or “bystander” model, neuronal death is mainly a consequence of the 
neuroinflammatory process.  It has even been proposed that after the inflammatory 
process becomes established, it can be self-propelled and maintained even if the virus 
were to be cleared from the CNS.  Nath and colleagues termed this phenomenon, where 
HIV-1 proteins act as a trigger to initiate a cascade of inflammation, the “hit and run 
phenomenon” (Nath et al. 1999).  Once activated by HIV, macrophages and microglia 
release numerous soluble products, including cytokines, chemokines, quinolinic and 
arachidonic acids, platelet activating factor, nitric oxide and growth factors.  These factors 
can exert neurotoxic effects through various mechanisms such as excitotoxicity, oxidative 
stress and neuronal apoptosis (a).  These released factors also further activate 
macrophages and/or microglia and promotes the proliferation and activation of astrocytes 
(b).  Activated astrocytes modify the permeability of the BBB and promote migration of 
monocytes to the brain (c).  Activation of astrocytes also leads to increased levels of 
intracellular calcium, glutamate and other neurotoxins resulting in the excitotoxic death of 
neurons (d).  
 
Although a number of the non-viral products secreted by activated macrophages, microglia 
and astrocytes, have proven to be neurotoxic, some may promote neuronal survival.  
Growth factors and some of the β-chemokines might play a neuroprotective role (e) and 
ultimately neurodegeneration follows a breakdown in the usual balance between 
neuroprotection and neurotoxicity (Kaul et al. 2005; González-Scarano and Martin-Garcia 




Figure 2.3 Mechanisms of neuroprotection and neurodegeneration in AIDS 
(González-Scarano and Martin-Garcia 2005) 
 
In the next section I will elaborate on the process of neuroinflammation by discussing the 
role of specific cytokines in the pathogenesis of HAND. 
 
C. Markers of inflammation 
 
In the previous section we’ve noted that HIV-1 does not infect neurones directly but 
induces damage indirectly through the release of neurotoxic mediators from activated 
uninfected, and/or HIV-1-infected macrophages and/or microglia.  These mediators 
include both cellular activation products and viral proteins.  Activated macrophages 
accumulate in the brains of infected individuals through monocytes that cross the BBB, 
carrying virus into the CNS and establishing local infection.  Macrophages also 
accumulate through the recruitment of additional monocytes from the periphery by 
chemotactic factors released from infected and activated macrophages or microglia in the 
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CNS.  These activated macrophages and microglia release a number of cytokines and 
other small molecules as well as viral proteins that influence uninfected adjacent cells and 
activate them, thus amplifying the inflammatory cascade.  These viral proteins and cellular 
products also have neurotoxic properties and can ultimately lead to neuronal injury and 
death directly, or through inducing activation of astrocytes (Yadav and Collman 2009). 
 
Cytokines are humoral proteins with multiple functions that regulate individual cells and 
tissues under physiological or pathological conditions.  They are important mediators of 
communication between the brain and endocrine or immune systems, and they play a key 
role in the induction and regulation of inflammation in the CNS.  The latter can cause 
progression or inhibition of neurodegeneration (Wang et al. 2006; Merrill and Benveniste 
1996).  Multiple pro- and anti-inflammatory cytokines are elevated in the CNS and/ or the 
cerebrospinal fluid (CSF) of patients with HIV-dementia.  Pro-inflammatory cytokines are 
mostly neurotoxic; anti-inflammatory cytokines are generally viewed as neuroprotective.  It 
is, however, not as simple as this and the functions of different cytokines overlap 
significantly.  The role of a specific cytokine can also change over time (Allan and Rothwell 
2003).  Cytokines in the CNS can be released as a result of direct viral infection or through 
the stimulation of uninfected mononuclear phagocytes by shed viral proteins to express 
elevated levels of cytokines (Rappaport et al. 1999; Sundar et al. 1991).  Many of these 
cytokines can augment further expression of cytokines leading to a pro-inflammatory 
environment in the CNS.  Additionally, several cytokines are directly or indirectly 
neurotoxic and can contribute to neuronal injury (Yadav and Collman 2009).  The most 
extensively studied cytokines in HIV-dementia are tumour necrosis factor alpha (TNF-α) 
and interleukin–1 beta (IL-1β), which are thought to play a major role in inducing neuronal 
death (Brabers and Nottet 2006; Wang et al. 2006; Zhao et al. 2001a; Achim et al. 1993).  
The anti-inflammatory cytokines, interleukin-10 (IL-10) and transforming growth factor beta 
(TGF-β), on the other hand, have been shown to have neuroprotective effects (Allan and 
Rothwell 2003).  Overall, it is probably the balance between pro- and anti-inflammatory 
cytokines in the brain that will determine whether injured neurons recover or die (Boche et 




Figure 2.4 Common mechanisms by which microglial activation and subsequent pro-
inflammatory cytokine release may contribute to neurodegenerative 
pathology. 




Tumour necrosis factor alpha (TNF-α)  
TNF-α is elevated in both the brain and CSF of patients with HAD (Tyor et al. 1992).  
When exposed to either gp120 or tat, in vitro, macrophages/microglia express elevated 
levels of TNF-α (Nuovo and Alfieri 1996; Yeung et al. 1995).   
 
TNF-α plays an important role in facilitating the entry of HIV-infected cells into the brain:  It 
increases the permeability of the BBB and induces the expression of the adhesion 
molecules intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1) and E-selectin on astrocytes and endothelial cells.  These proteins allow HIV-1 
infected monocytes to transmigrate into the CNS and they up-regulate the expression and 
release of various chemokines in the CNS that attract monocytes and macrophages  
(Winkler and Beveniste 1998; Fiala et al. 1997; Hurwitz et al. 1995; Collins et al. 1995).    
Gelbard and colleagues found that TNF-α might exert toxic effects by over stimulating the 
Ν-methyl-D-aspartate (NMDA) glutamate receptor on neurones (Gelbard et al. 1993).  In 
conjunction with stromal cell-derived factor 1 (SDF-1), a chemokine, TNF-α also increases 
the release of the neurotransmitter glutamate from astrocytes and microglia (Bezzi et al. 
2001).  In addition, TNF-α inhibits the re-uptake of glutamate by astrocytes.  Along with 
gp120, it also stimulates macrophages and microglia to release L-cysteine, which is a 
precursor to glutamate (Yeh et al. 2000).  These resultant excessive levels of extracellular 
glutamate may contribute to neuronal cell death in HAD (Yadav and Collman 2009). 
 
In vitro exposure of neurons to gp120 and tat results in elevated levels of sphingomyelin 
and ceramide, a process probably mediated by TNF-α and IL-1β expressed by 
macrophages and microglia (Yeung et al. 1995).  Sphingomyelin is a major class of 
membrane phospholipids that, when hydrolysed by sphingomyelinase, produces 
ceramide.  Ceramide is a second messenger thought to be involved in apoptosis.  Both 
TNF-α and IL-1β are thought to activate membrane-associated sphingomyelinase, and 
sphingomyelin and ceramide levels have been shown to be elevated in the brain tissue 
and CSF of HIV-1 infected patients with cognitive impairment.  TNF-α-induced 
sphingomyelin and ceramide can, furthermore, activate HIV-1 transcription.  There is also 
evidence that ceramide can lead to the production of neurotoxic radical oxygen species 
(ROS) (Haughey et al. 2004).  TNF-α may play a further neurotoxic role by inducing the 
expression of fractalkine (FKN) in neurones and astrocytes.  When FKN binds to its 
receptor CX3CR1, it induces adhesion, chemo-attraction and activation of other 
inflammatory cells including macrophages and microglia (Erichsen et al. 2003).  TNF-α 
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also induces the production of platelet activating factor (PAF) that is another significant 
mediator of neurotoxicity in HAD (Gelbard et al. 1994). 
 
TNF-α alters the function of astrocytes, macrophages and microglia, which ultimately leads 
to the release of more pro-inflammatory cytokines.  Astrocytes stimulated by TNF-α also 
appear themselves to be susceptible to apoptosis (Saha and Pahan 2003). 
 
Besides the effects that TNF-α can exert individually, it has also been demonstrated to 
enhance the toxic effects of other inflammatory mediators present in the brains of patients 
with HAD (Brabers and Nottet 2006). 
 
TNF-α is pro-inflammatory, can lead to further activation and recruitment of macrophages 
and microglia, and is also a direct neurotoxin.  Its multiple effects ultimately result in an 
accumulation of excessive amounts of excitatory molecules in the extracellular space.  
This leads to overstimulation of the NMDA receptor, resulting in excessive calcium (Ca2+) 
influx and the formation of nitric oxide (NO) and superoxide anion, which results in 
neuronal apoptosis or necrosis. TNF-α can also activate astrocytes and decrease the 
uptake of the excitotoxic neurotransmitter glutamate, thus potentiating glutamate 
neurotoxicity (Yadav and Collman 2009; Brabers and Nottet 2006; Bonfoco et al. 1995; 
Lipton 1994). 
 
There are, however, data suggesting that TNF-α can have neuroprotective properties.  
TNFα activation of nuclear factor kappa beta (NF-κB) can protect neurones against 
apoptosis induced by oxidative and metabolic insults and also by enhancing cellular 
calcium homeostasis (Glazner and Mattson 2000; Barger et al. 1995).  Data in support of 
the neuroprotective properties of TNF-α are, however, incomplete and these have not 
always been acquired in relation to HAD studies (Brabers and Nottet 2006).  
 
Interleukin-1 beta (IL-1β) 
IL-1β is another cytokine found to play a central role in the inflammation and neurotoxicity 
associated with HAD (Brabers and Nottet 2006; Tyor et al. 1992).  It shares many 
neurotoxic properties with TNF-α (Yadav and Collman 2009).  IL-1 is a macrophage 
cytokine whose expression is tightly regulated.  It is produced as pro-IL-1β and is then 
cleaved by the IL-1β converting enzyme, caspase-1, to produce active IL-1β (Thornberry 
et al. 1992).  Neurones, endothelial cells and astrocytes express caspase-1, but 
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expression is highest in activated macrophages and microglia (Zhao et al. 2001a).  IL-1β 
activates astrocytes with the subsequent production of TNF-α and inducible nitric oxide 
synthase (iNOS) via activation of NF-κβ (Jana et al. 2005; Zhao et al. 2001a).  The 
formation of iNOS results in the expression of NO, which is neurotoxic and also increases 
BBB permeability (Chao et al. 1996).  When microglia are exposed to gp120, they produce 
ROS and also overexpress IL-1β (Viviani et al. 2001).  Like TNF-α, IL-1β is responsible for 
NMDA receptor-mediated increased levels of toxic Ca2+ levels in neurones (Yeh et al. 
2000).  It can also induce expression of ICAM, VCAM and E-selectin on endothelial cells 
and astrocytes, leading to increased monocyte infiltration into the brain (Winkler and 
Beveniste 1998; Collins et al. 1995).  IL-1β furthermore induces the expression of 
monocyte chemotactic protein-1 (MCP-1) by astrocytes, a potent chemo-attractant for 
mononuclear phagocytes (Oh et al. 1999).  IL-1B can also induce the expression of 
ceramide, thought to play a role in ROS formation and neuronal apoptosis  (Haughey et al. 
2004). 
 
Like TNF-α, IL-1β has been shown to play a neuroprotective role in HAD through the 
induction of NO production.  Depending on its redox status, NO has been shown to limit 
viral replication and reactivation in acutely infected cells (Mannick et al. 1999).  IL-1β can 
induce the expression of chemokine (C-C motif) ligand 5 (CCL5), also known as 
Regulated on Activation, Normal T Cell Expressed (RANTES), from astrocytes, which can 
protect neurones against apoptosis (Kim et al. 2004; Bruno et al. 2000).  RANTES can 
also prevent HIV-1 infection of macrophages and microglia by competitively binding to its 
receptor, C-C chemokine receptor type 5 (CCR5) (Brabers and Nottet 2006). 
 
Interleukin-10 (IL-10) 
IL-10 is an important anti-inflammatory cytokine that can limit and terminate the 
inflammatory response.  It also regulates the differentiation and proliferation of immune 
cells.  Numerous studies, both in vivo and in vitro, suggest that IL-10 has a major role in 
inflammatory, malignant and autoimmune diseases (Asadullah et al. 2003).  IL-10 controls 
inflammatory processes by potently down-regulating the expression and actions of pro-
inflammatory cytokines such as IL-1 and TNF-α, chemokines, adhesion molecules, as well 
as antigen-presenting and co-stimulatory molecules in brain monocytes or macrophages  
(Konsman et al. 2002; Kelly et al. 2001; Moore et al. 2001).  IL-10 most likely exerts this 
anti-inflammatory property by inhibiting the transcription factor NF-κB.  NF-κB is 
responsible for the production of numerous pro-inflammatory proteins (Wang et al. 1995).  
 18 
Macrophages are the major source of IL-10.  They can be stimulated to produce IL-10 by 
several endogenous and exogenous factors amongst which are endotoxin and TNF-α  
(Meisel et al. 1996; Platzer et al. 1995).  IL-10 supports the maturation of monocytes to 
macrophages (Allavena et al. 1998).  In general, it inhibits all activities that promote 
inflammation while enhancing the immuno-suppressive activities of these monocytes and 
macrophages (Buchwald et al. 1999). 
 
Transforming growth factor beta (TGF-β) 
TGF-β belongs to a family of multifunctional peptides that control the growth, differentiation 
and functioning of a variety of target cells (Roberts et al. 1990).  It is a potent cytokine with 
an essential role in active immune suppression (Mantel and Schmidt-Weber 2011).  Wahl 
and colleagues demonstrated that TGF-β1 is present in the brains of AIDS patients, but 
not in normal brain tissue, and its presence is likely to be neuroprotective (Wahl et al. 
1991).  TGF-β is normally found in high concentrations in HAD (Dhar et al. 2006).  
Monocytes are responsible for TGF-β production, and TGF-β1 is the isoform most 
abundantly expressed (Lotz and Seth 1993).  TGF-β plays a neuroprotective role in 
neurodegenerative diseases by limiting inflammation (Flanders et al. 1998), and by 
protecting glial cells against injury by nitric oxide synthase (Bottner et al. 2000).  TGF-β1 
has been shown to directly down-regulate the production of the pro-inflammatory cytokines 
IL-1β and TNF-α.  The presence of TGF-β before the excitotoxic insult may make the 
acute inflammatory response less aggressive (Bogdan et al. 1992).  TGF-β was one of the 
first cytokines shown to induce monocyte deactivation (Chantry et al. 1989; Tsunawaki et 
al. 1988).  It can also stimulate or inhibit expression of other cytokines in macrophages 
and microglia (Musso et al. 1990; Chantry et al. 1989).   
 
Although TGF-β has been considered an anti-inflammatory cytokine, Matsumara et al. 
provided evidence that TGF-β acts as a pro-inflammatory cytokine in the brain  
(Matsumura et al. 2008).  Their research also showed that the increase in TGF-β 
concentrations in the CSF preceded that of other pro-inflammatory cytokines in the blood.  
This implies that the increase in TGF-β in the CSF was not likely to have been induced by 
cytokines in the serum.  A possible alternative system for transmission of the peripheral 
inflammation/infection signal to the brain has therefore been proposed: peripheral 
information may be transmitted via the vagus nerve (Romanovsky 2004), leading to this 
early increase of active TGF-β in the brain (Matsumura et al. 2007).  Another possible 
mechanism by which TGF-β contributes to the pro-inflammatory environment is through 
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chemotaxis of monocytes, thus causing their migration to the brain.  Even at very small 
concentrations, TGF-β is an extremely potent chemotactic agent for human peripheral 
blood monocytes.  At higher concentrations, TGF-β can also activate these recruited 
monocytes to secrete other pro-inflammatory cytokines such as IL-1 and TNF-α (Wahl et 
al. 1987).   The ability of TGF-β to further activate the synthesis of TNF-α is probably a 
major pathway leading to the destruction of neurones (Rappaport et al. 1999; Sawaya et 
al. 1998). 
 
Wahl and colleagues suggested an association between HIV-1 infection and the 
production of TFG-β1 (Wahl et al. 1991).  TGF-β stimulates replication of HIV in infected 
monocytes and also promotes virus spreading under certain in vitro conditions (Lotz and 
Seth 1993).  Tat protein has been shown to increase the expression of TGF-β1 in the brain  
(Sawaya et al. 1998; Cupp et al. 1993).  TGF-β1 levels were significantly elevated in the 
CSF of patients with HIV-1 infection and CD4<500cells/mm3, compared to HIV-positive 
patients with CD4>500cells/mm3 and HIV-negative controls (Johnson et al. 2004).  
 
From the literature it is clear that TGF-β plays a highly divergent role in the CNS and that 
its effects are bidirectional, pro-inflammatory or anti-inflammatory, depending on the type 
and status of the cell that receives its action (Matsumura et al. 2008). 
 
Summary 
Cytokines comprise a group of small polypeptides with tremendous diversity in their 
potential actions (Smith et al. 2012).  It is clear that when cytokines are expressed 
inappropriately, their deleterious effects can exceed the beneficial role that they play in 
resistance of the host to infection.  Plenty of evidence supports the active participation of 
pro-inflammatory cytokines in neuronal death, astrogliosis and demyelination found with 
immune and non-immune brain injury.  Overexpression of TGF-β can convert its protective 
functions to a pathogenic state (Lotz and Seth 1993). 
 
In the above paragraphs, I discussed how HIV-1 invades the brain early when infected 
monocytes migrate across the BBB.  This leads to HIV-1 infection of the resident 
macrophages and microglia in the brain, which initiates a neuroinflammatory process that 
ultimately causes the neurocognitive disorders associated with HIV-1.  Besides this initial 
neuroinvasion and the resulting neuroinflammatory process, other factors associated with 
progressive HIV infection in the periphery may be necessary to eventually trigger the 
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development of HAND (Gartner 2000).  In the following paragraphs I will discuss the link 
between systemic inflammation and inflammation in the brain. 
 
D. The link between the peripheral/systemic circulation and inflammation in the CNS 
 
 
Figure 2.5 The relationship between systemic infection, CNS inflammation, 
neurodegeneration and cognitive impairment in HIV infection 
 
The role of the BBB in HIV-1 CNS infection 
The BBB functions as a protective mechanism for the brain.  It restricts the entry of cellular 
components of the immune system, relatively excluding them from immune surveillance 
(Berger and Avison 2004).  The brain is however not an “immune-privileged” organ as was 
previously thought and it does also respond to peripheral inflammatory stimuli and immune 
responses (Wärnberg et al. 2009).   The CNS can therefore be affected through the 
actions of peripheral cytokines that cross the BBB.   
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HIV infection is a well-known cause of BBB disruption, and targets many of the cellular 
and structural components of the BBB.  The initial early entry of HIV, however, occurs 
against a setting of normal BBB structure and function (“Trojan Horse” mechanism).  Later 
HIV-associated compromise of the BBB, through pro-inflammatory mechanisms or direct 
impact of HIV proteins, causes the BBB to become more leaky.  This may facilitate an 
accelerated entry of HIV into the CNS, which may have a significant impact on the clinical 
progression of HIV-associated CNS disease (Wang et al. 2008; Zhou et al. 2006; Berger 
and Avison 2004).  
 
Increased monocyte trafficking into the CNS 
From the literature it is clear that activated monocytes play a key role in the pathogenesis 
of HIV-associated cognitive impairment (González-Scarano and Martin-Garcia 2005; 
McArthur et al. 2003; Kaul et al. 2001).  Monocytes are produced, and also mature, in the 
bone marrow.  Increased numbers of monocytes and resident macrophages have been 
found in the bone marrow of patients with AIDS (Titius et al. 2009; Kaloutsi et al. 1994).  
Uncontrolled HIV replication and the resulting immunodeficiency alter the myeloid 
differentiation pathway.  HIV infection therefore results in increased numbers of circulating 
and activated monocytes from the bone marrow (Fischer-Smith and Rappaport 2005; 
Thieblemont et al. 1995).  These cells invade the CNS and have been clearly associated 
with the development of HIV dementia (Gartner 2000; Pulliam et al. 1997; Tyor et al. 1992) 
Pulliam et al also found a unique subset of activated CD14/CD16 and CD14/CD69 
expressing monocytes in patients with AIDS dementia.  They demonstrated that the CD69 
monocytes are neurotoxic in vitro and suggested that this subgroup of monocytes might be 
the link between the periphery and parenchymal damage in the brain (Pulliam et al. 1997).  
The dramatic increase in the total number of brain macrophages associated with HIV-
encephalitis (HIVE), the pathological hallmark of HIV-dementia, thus appears to be due to 
trafficking of monocytes/macrophages from the periphery into the CNS, and not from local 
microglial proliferation (Fischer-Smith et al. 2004).  It therefore follows that certain events 
in the periphery lead to altered monocyte/macrophage homeostasis with a resultant 
increased CNS invasion of activated HIV-1 infected monocytes.  This is the so-called late 
invasion model (Fischer-Smith and Rappaport 2005). 
 
Chronic systemic infection and inflammation 
Numerous studies have recognized systemic inflammation as a key driver of HIV-1 
pathogenesis, both in the periphery and in the CNS (Deeks 2009; Brenchley et al. 2006b).  
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Recent research has also begun to show possible dynamic interrelationships between the 
CNS and systemic disease (Rausch and Davis 2001).  As discussed previously, systemic 
HIV infection of monocytes and T cells ultimately leads to CNS infection and 
neurodegeneration through the activation of macrophages and microglial cells in the brain 
(Nottet and Gendelman 1995).  Microglial cells can be activated by HIV-infected and/or 
uninfected immune-reactive monocytes and lymphocytes (Yoshioka et al. 1995).  It is 
possible that microglial cells can be activated in response to systemic infection before or 







Figure 2.6 Schematic representation of the “cross-talk” between components of the 
BBB and cells of the CNS in microglial activation in AIDS. 
(Langford and Masliah 2001) 
 
During HIV infection, signals originating from activated monocytes in the bloodstream may 
activate microglial cells through a cascade of stimuli that cross the BBB (Figure 2.6A).  
Resting microglia may also be activated by activated macrophages/microglia in the brain 
(Figure 2.6B) (Gebicke-Haerter et al. 1996).  Systemic and CNS HIV infection therefore 
act together in the activation of microglia leading to HIVE and increased 
neurodegeneration (Langford and Masliah 2001).  Pro-inflammatory mediators produced 
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systemically following infection can signal to the brain, thus leading to activation of 
microglial cells that ultimately induce adaptive metabolic and behavioural changes 
(“sickness behaviour”).  Induction of this sickness response is associated with the 
expression of pro-inflammatory cytokines such as IL-1β and TNF-α, both in the periphery 
and in the brain (Hosoi et al. 2002).  In normal healthy persons this is part of the immune 
system’s defence against disease (and part of the generation of fever), but in patients with 
chronic neurodegenerative disease, systemic inflammation leads to accelerated 
neuroinflammation and increased neuronal death (Minghetti 2005; Perry et al. 2003).  
Ryan et al measured increased levels of soluble TNF-α type II receptor and soluble CD14 
in the plasma of HIV-1 infected subjects with cognitive impairment and brain atrophy  
(Ryan et al. 2001).  CD14 is found principally on human monocytes and increased release 
of soluble CD14 has been observed from activated monocytes (Landmann et al. 1996).  
Increased levels of soluble CD14 also correlate with HIV disease progression (Lien et al. 
1998).  These findings support an interplay between peripheral immune responses and 
cognitive dysfunction in advanced HIV-1 disease (Ryan et al. 2001).   
 
Untreated HIV infection is associated with recurrent systemic and opportunistic infections, 
and therefore also with increased circulating levels of pro-inflammatory cytokines such as 
TNF-α, IL-1B and IL-6.  These cytokines can cross the BBB or circulating cytokines can 
affect the CNS indirectly to produce more cytokines in the CNS (Wong et al. 1995; 
Watkins et al. 1995; Hashimoto et al. 1991).  The peripheral nervous system can influence 
the brain by sending signals via the peripheral or cranial nerves, especially the vagus 
nerve.  We can, therefore, see that the peripheral and central cytokine compartments 
appear to be integrated and that they might synergize or inhibit each other (Szelenyi 
2001). 
 
Immune activation is a strong predictor of HIV disease progression (Brenchley et al. 
2006a).  A possible trigger of chronic systemic immune activation in HIV-1 infection is 
elevation of a plasma endotoxin, bacterial lipopolysaccharide (LPS).  Elevated levels of 
LPS are a consequence of translocation of bacterial products across a gut mucosa barrier, 
associated with HIV-mediated depletion of mucosal CD4 T lymphocytes (Douek 2007; 
Brenchley et al. 2006b).  LPS triggers monocyte activation and can also compromise the 
integrity of the BBB, which permits entry of increasing numbers of HIV-infected monocytes 
into the brain (Ancuta et al. 2008; Zhou et al. 2006).  Using an in vivo novel mouse model, 
Wang and colleagues demonstrated that HIV-1 infection increased the ability of 
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monocytes to enter the brain and also increased sensitivity of the BBB to disruption by 
LPS (Wang et al. 2008).  Through these mechanisms circulating LPS may therefore be 
linked to the development of HAD.  The elevated levels of LPS that lead to an immune 
activated state associated with HIV-infection also causes increased levels of circulating 
cytokines (Douek 2007; Brenchley et al. 2006b). 
 
From the above evidence, it follows that there is an association between the systemic 
inflammatory response and the numbers of activated macrophages and microglia in the 
CNS, neuronal damage, and cognitive dysfunction (Glass et al. 1995).  We can therefore 
postulate that repeated or chronic systemic infections and inflammation – as is common in 
HIV – may drive and enhance the process of neuroinflammation, and ultimately that of 
neurodegeneration and the development of HAND, through signalling from the peripheral 
blood to the CNS (Gannon et al. 2011; Ancuta et al. 2008). 
 
E. Summary of the neuropathogenesis of HAND (Figure 2.7) 
 
During HIV-1 infection, chronic immune activation in the periphery develops as a result of 
anti-HIV-1 immune responses, elevated levels of LPS due to microbial translocation from 
the gut, and viral proteins such as gp120 and Tat.  Immune activation is believed to drive 
systemic immunopathogenesis but also leads to an expanded subset of activated 
monocytes, some of which are also infected with HIV-1.  These monocytes have 
enhanced migratory capacity and traffic through the BBB, which is compromised by the 
action of viral proteins, pro-inflammatory mediators, and LPS.  Once inside the CNS, these 
cells differentiate into macrophages and release viral particles that infect other cells with 
HIV-1.  Activated macrophages also release viral proteins, cytokines (e.g. TNF-α, IL-1β), 
and chemokines that activate neighbouring macrophages and microglia and therefore 
sustain the neuroinflammatory response.  These factors also activate astrocytes.  
Released chemokines such as MCP-1 and SDF-1α further recruit monocytes into the 
CNS.  Some of these chemokines also up-regulate adhesion molecules on various cell 
types that further enhance recruitment of inflammatory cells.  These processes lead to 
accumulation of activated monocytes/macrophages in the brain that correlates with 
neurological injury.  Neuronal injury results from the combined effects of neurotoxic viral 
proteins released from infected monocytes/macrophages, neurotoxic cytokines released 
from infected and non-infected activated cells, and soluble macrophage activation 
products like quinolinic acid and platelet activating factor that lead to neuronal cell death.  
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Dysfunctional astrocytes also contribute through the dysregulated homeostasis of the 




Figure 2.7 Summary of the neuropathogenesis of HAND 
(Yadav and Collman 2009) 
 
Next I shall examine briefly the neuropathological and clinical features of HAND.  
 
 
2.3.2 Pathological correlates of HAND 
 
Chronic neuroinflammation results in the neuropathological abnormalities collectively 
called HIV-1 encephalitis (HIVE) (Yadav and Collman 2009; Langford et al. 2003; Zheng 
and Gendelman 1997).  Simian immunodeficiency virus (SIV) encephalitis models and 
human autopsies have been crucial in advancing our understanding of the pathology of 
HAND (McArthur et al. 2010).  Neuropathologically, HIVE is characterized by: the 
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infiltration of macrophages; the formation of microglial nodules and multinucleated giant 
cells (MNGC) through fusion of HIV-infected macrophages in central white matter and 
deep grey matter; widespread reactive astrogliosis and the loss of neurons; and myelin 
pallor – the loss of myelin surrounding neuronal axons, indicating damage to 
oligodendrocytes (Hazleton et al. 2010; Lawrence and Major 2002; Gendelman et al. 
1994).  It is interesting that these pathological features are most closely associated with 
the clinical signs of HAD, and that the presence of macrophages and microglia is a better 
correlate of HAD than is the presence of HIV-infected cells or the viral antigen load in the 
brain (Kaul et al. 2005; Glass et al. 1995). 
 
Since the advent of cART, HIVE is now believed to have reduced considerably, while more 
subtle neuropathological alterations such as brain infiltration of blood-borne monocytes 
and more limited gliosis are common (Kraft-Terry et al. 2010; Everall et al. 2005).  Vago 
and colleagues did a retrospective study of 1597 autopsy cases in Italy and determined 
the frequency of HIVE as 54% before the introduction of cART with a subsequent 60% 
decline in the cART era (Vago et al. 2002). 
 
The neuropathological changes and most productive HIV infection are seen within the 
basal ganglia, brainstem and deep white matter (Brew et al. 1995; Kure et al. 1991).  This 
regional predisposition probably accounts for the mostly subcortical pattern of the clinical 
deficits in HAND (McArthur et al. 2010). 
 
2.3.3 Clinical features of HAND 
 
A. Classification  
 
Since 1991, the guidelines published by the AIDS Task Force of the American Academy of 
Neurology (AAN) were used to diagnose the cognitive impairment related to HIV-1 
infection.  These criteria defined two levels of HIV-associated cognitive impairment: HIV-
dementia (HIV-D) and minor cognitive and motor disorders (MCMD).  In 1995, Grant and 
Atkinson expanded the AAN system to include the additional diagnosis of “sub-syndromic 
neurocognitive impairment”.  This was used to characterize patients with mild 
neurocognitive deficits that did not interfere with daily functioning (Grant and Atkinson 
1995).  In 2007 the HIV Neurobehavioral Research Center (HNRC) proposed a refinement 
of the AAN criteria which recognized the following three conditions: asymptomatic 
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neurocognitive impairment (ANI), HIV-associated mild neurocognitive disorder (MND), and 
HIV-associated dementia (HAD).  ANI and MND are defined as scoring at least one 
standard deviation below the mean of a control population in at least two domains of 
cognitive functioning.  However, in MND there is mild impairment in ADLs.  MND is similar 
to MCMD as previously defined by the AAN criteria.  HAD is defined by a score of at least 
two standard deviations below the mean of a control population in at least two cognitive 
areas, and with marked impairment in ADLs.  The revised research criteria require that the 
impairment is not due to delirium and cannot be fully explained by comorbid conditions  















HIV-associated asymptomatic neurocognitive impairment (ANI)* 
1. Acquired impairment in cognitive functioning, involving at least two ability domains, documented by performance of at least 
1.0 SD below the mean for age-education-appropriate norms on standardized neuropsychological tests. The 
neuropsychological assessment must survey at least the following abilities: verbal/language, attention/working memory, 
abstraction/executive, memory (learning, recall), speed of information processing, sensory-perceptual, motor skills. 
2. The cognitive impairment does not interfere with everyday functioning. 
3. The cognitive impairment does not meet criteria for delirium or dementia. 
4. There is no evidence of another pre-existing cause for the ANI° 
*If there is a prior diagnosis of ANI, but currently the individual does not meet criteria, the diagnosis of ANI in remission can be made. 
°If the individual with suspected ANI also satisfies criteria for a major depressive episode or substance dependence, the diagnosis of ANI should be deferred to a 
subsequent examination conducted at a time when the major depression has remitted or at least 1 month after cessation of substance use. 
HIV-associated mild neurocognitive disorder (MND)** 
1. Acquired impairment in cognitive functioning, involving at least two ability domains, documented by performance of at least 
1.0 SD below the mean for age-education-appropriate norms on standardized neuropsychological tests. The 
neuropsychological assessment must survey at least the following abilities: verbal/language, attention/working memory, 
abstraction/executive, memory (learning, recall), speed of information processing, sensory-perceptual, motor skills. Typically 
this would correspond to an MSK scale stage of 0.5 to 1.0. 
2. The cognitive impairment produces at least mild interference in daily functioning (at least one of the following): 
a. Self-report of reduced mental acuity, inefficiency in work, homemaking, or social functioning. 
b. Observation by knowledgeable others that the individual has undergone at least mild decline in mental acuity with 
resultant inefficiency in work, homemaking, or social functioning. 
3. The cognitive impairment does not meet criteria for delirium or dementia. 
4. There is no evidence of another pre-existing cause for the MND°° 
**If there is a prior diagnosis of MND, but currently the individual does not meet criteria, the diagnosis of MND in remission can be made. 
°°If the individual with suspected MND also satisfies criteria for a severe episode of major depression with significant functional limitations or psychotic features, or 
substance dependence, the diagnosis of MND should be deferred to a subsequent examination conducted at a time when the major depression has remitted or at least 1 
month after cessation of substance use. 
HIV-associated dementia (HAD)*** 
1. Marked acquired impairment in cognitive functioning, involving at least two ability domains, typically the impairment is in 
multiple domains, especially in learning of new information, slowed information processing, and defective 
attention/concentration. The cognitive impairment must be ascertained by neuropsychological testing with at least two 
domains 2 SD or greater than demographically corrected means. (Note that where neuropsychological testing is not 
available, standard neurological evaluation and simple bedside testing may be used, but this should be done as indicated in 
algorithm, see below.) Typically this would correspond to an MSK scale stage of 2.0 or greater. 
2. The cognitive impairment produces marked interference with day-to-day functioning (work, home life, social activities). 
3. The pattern of cognitive impairment does not meet criteria for delirium (e.g. clouding of consciousness is not a prominent 
feature); or, if delirium is present, criteria for dementia need to have been met on a prior examination when delirium was not 
present. 
4. There is no evidence of another pre-existing cause for the dementia (e.g. other CNS infection, CNS neoplasm, 
cerebrovascular disease, pre-existing neurologic disease, or severe substance abuse compatible with CNS disorder)°°° 
*** If there is a prior diagnosis of HAD, but currently the individual does not meet criteria, the diagnosis of HAD in remission can be made. 
°°° If the individual with suspected HAD also satisfies criteria for a severe episode of major depression with significant functional limitations or psychotic features, or 
substance dependence, the diagnosis of HAD should be deferred to a subsequent examination conducted at a time when the major depression has remitted or at least 1 
month after cessation of substance use. Note that the consensus was that even when major depression and HAD occurred together, there is little evidence that 
pseudodementia exists and the cognitive deficits do not generally improve with the treatment of depression. 
 
Table 2-1 Revised research criteria for HAND 
 (Antinori et al. 2007) 
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B. Clinical presentation 
 
HAND is a spectrum of disorders ranging from mild impairment to severe dementia (Ellis 
et al. 2009).  Individuals with HIV can develop cognitive impairment in a number of 
different domains and the clinical features of HAND are both subcortical and cortical  
(Hazleton et al. 2010).  The domains most affected by HAND are attention, learning and 
memory, motor function, psychomotor speed, executive function, and language (Power et 
al. 2009; McArthur et al. 2005).  During the early stages of HAND, clinical symptoms may 
be absent (ANI) or subtle (MND) but they can progress in severity to a debilitating 
dementia (HAD).  When clinically evident, symptoms fall into the main categories of 
cognitive, behavioural and motor dysfunction (Nath and Berger 2004; Jannsen et al. 1991; 
Navia et al. 1986).   
 
MND may have functional consequences on work and medication adherence, but can 
present a diagnostic challenge because individuals typically present with vague cognitive 
complaints and a relatively normal neurological examination.  Neuropsychological tests 
are useful tools for demonstrating early cognitive dysfunction (Nath and Berger 2004). 
 
In the pre-cART era HAD most commonly presented in patients with advanced 
immunosuppression (e.g. CD4 cell counts below 200 and elevated viral loads), co-existing 
systemic disease and clinical hallmarks of advanced AIDS.  Since the start of the cART 
era dementia is sometimes the presenting or only evidence of HIV infection before the 
patient exhibits any other illness characteristic of impaired immunity.  CD4 cell counts can 
now be normal or near normal when a patient presents with HAD (Dore et al. 2003; Price 
et al. 1988; Navia and Price 1987).  The early stages of HAD are frequently characterised 
by the symptoms of memory loss, mental slowing, reading and comprehension difficulties, 
as well as apathy.  The initial symptoms of dementia due to HIV can be subtle and can be 
overlooked or misdiagnosed as depression.  Typical cognitive deficits of HAD are: memory 
loss selective for impaired retrieval; impaired ability to manipulate acquired knowledge; 
personality changes that are characterized by apathy, inertia and irritability; and general 
slowing of all thought processes (McArthur et al. 2003).  Gait disturbance, with non-
specific stumbling and tripping, and impairment of fine manual dexterity are common early 
motor manifestations.  Motor examination findings reveal impaired rapid eye and limb 
movement, diffuse hyperreflexia, frontal lobe release signs, and sometimes Parkinsonism  
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(McArthur et al. 2003).  Clinical presentation can, however, vary considerably between 
affected individuals (Navia et al. 1986). 
 
C. Clinical course 
 
Like the clinical presentation, the course of HAND also varies considerably.  There is now 
evidence that affected individuals may show marked recovery of their cognitive functions 
with effective combination antiretroviral therapy (cART), or worsening of HAND with 
advanced AIDS (Woods et al. 2009).  HIV-infected individuals may develop ANI, then 
progress to MND, and then HAD but clinical progression can also fluctuate (Hazleton et al. 
2010; Bouwman et al. 1998).  Navia et al described the typical presentation of HIV-
dementia and found the course of the disease, in most patients, to be steadily progressive, 
interrupted by episodes of abrupt acceleration.  In 20% of patients a slowly progressive 
course was observed (Navia et al. 1986).  The presence of MND may be a predictor of 
HAD, or is at least associated with the neuropathological changes of HIV encephalitis  
(Joska et al. 2010d; Cherner et al. 2002).  MND may also indicate a worse prognosis in 
AIDS (Sacktor et al. 1996).  Several studies, however, do suggest that normalization of 
symptoms is possible (Valcour et al. 2004a; Sacktor et al. 2002; Heaton et al. 1995). 
Antinori et al found that a substantial proportion of HIV-infected persons’ symptoms 
fluctuate between normal to abnormal (Antinori et al. 2007).  
 
D. Functional impact 
 
HIV-positive patients with neuropsychological impairment are at higher risk of dying than 
those without impairment (Ellis et al. 1997).  Neurocognitive disorders associated with HIV 
are present in up to 50% of HIV-positive patients with the milder forms of HAND being 
present in at least 30% to 40% of symptomatic HIV-positive adults (Joska et al. 2010d; 
Sacktor et al. 2002).  The milder forms of HAND are more prevalent in the cART era and 
survival is considerably longer (Antinori et al. 2007).  Despite the remarkable improvement 
in survival rates since the introduction of cART, HAND remain a significant public health 
concern (Woods et al. 2009) and may occur even in those patients who do not have any 
other evidence of active HIV disease (Antinori et al. 2007).  These disorders, even the 
milder forms of HAND, impact negatively on social and occupational functioning.  
Individuals may be non-adherent to cART regimens, and they may miss clinical 
appointments.  They may also be more vulnerable to sexual abuse and more likely to 
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engage in high-risk behaviours (Alfahad and Nath 2013; Gras and Kaul 2010; Gorman et 
al. 2009).  
 




The diagnosis of HAND is primarily clinical.  It relies on a neuropsychological, psychiatric 
and medical evaluation to identify the clinical syndrome and to exclude any alternative 
diagnoses or confounding conditions (Barber et al. 2013; Joseph et al. 2009).   
 
Based on current diagnostic nomenclature, the diagnosis of HAND requires assessment of 
at least five domains of neurocognitive functioning known to be affected by HIV infection: 
executive function, episodic memory, speed of information processing, motor skills, 
attention/working memory, language, and sensoriperception (Antinori et al. 2007).  In an 
ideal environment, these domains would be assessed using a performance-based 
neurocognitive test battery and interpreted using demographically appropriate normative 
data (Woods et al. 2009).  In busy primary care settings and countries with limited 
resources, clinicians usually do not have access to a detailed neuropsychological test 
battery and therefore use clinical assessments or brief screening tools such as the 
International HIV Dementia Scale (IHDS) (Woods et al. 2009; Sacktor et al. 2005).   
 
The diagnosis of HAND often depends on demonstrating a decline in everyday 
functioning, but the assessment of functional impairment is an intricate and complicated 
process (Woods et al. 2009).  There are also currently no widely agreed-upon clinical 
measures of everyday functioning.  The assessments used in research settings are 
lengthy to administer and therefore not widely used in a clinic setting (Moore et al. 2007).  
Assessments of everyday functioning rely on self-report but are usually complemented by 
reports from partners or caregivers where patients have cognitive impairment or poor 





Figure 2.8 Proposed decision-tree for diagnosing HIV-associated Neurocognitive 
Disorders 
 (Woods et al. 2009) 
 















Another approach used to detect HIV-associated cognitive impairment is the Global Deficit 
Score (GDS), which summarizes the results of a reduced subset of neuropsychological 
tests.  Demographically corrected test data on individual neuropsychological measures are 
converted to deficit scores ranging from no impairment to severe impairment.  The deficit 
scores are averaged to create a global deficit score.  The GDS weights 
neuropsychological data by considering both the number and severity of deficits in an 
individual’s performance throughout the test battery, giving relatively less weight to 
superior performances and/or those within normal limits.  The GDS has been shown to 
effectively predict mild cognitive impairment in HIV infected subjects (Carey et al. 2004a; 
Heaton et al. 1995).  It is a useful tool for classifying cognitive impairment in HIV, as it 
does not require the use of functional assessments like the revised criteria for HAND.  The 
GDS is a more objective measure, because HIV-positive patients often visit healthcare 
centres alone and without someone to provide collateral information (Valcour et al. 2011). 
 
Medical evaluation involves a general physical and a neurological examination.  The 
neurological examination should assess the presence of peripheral neuropathy, motor 
tone and power, involuntary movements, primitive reflexes and gait.  Imaging studies, 
such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy 
(MRS), are commonly used in developed countries to exclude CNS opportunistic 
infections, and also to identify the characteristic radiological changes present in HAD.  
These imaging studies are, however, not always available in resource-poor countries such 
as South Africa.  CSF analysis is indicated in febrile patients or those with acute 
encephalopathy to exclude cryptococcal or tuberculosis (TB) meningitis.  In the more 
typical non-febrile patients it is generally not needed, provided that imaging can be used to 
exclude CNS opportunistic infections (McArthur et al. 2005). 
 
There is still an urgent need for an objective, scalable and quantitative biomarker profile 
for HAND.  The ideal biomarker for HIV-associated cognitive impairment would: 1) 
diagnose HAD and the milder forms of HAND, 2) identify patients at risk, 3) detect disease 
progression, 4) confirm arrested or static encephalopathy, and 5) measure treatment 
response.  It is not plausible that a single biomarker would be sufficient for all these aims 
and the search should rather be for complementary markers (McGuire 2009).  Given that 
systemic and localized inflammation is considered an underlying pathogenic mechanism of 
HAND, the change in CSF cytokine levels during HIV might help to identify HAND.  In a 
preliminary study by Yuan et al, there was an association between the increased levels of 
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cytokines in the CSF and HIV-associated neurocognitive impairment.  They concluded that 
cytokines might provide a biomarker profile for HAND (Yuan et al. 2013).  The CSF 
compartment may, however, not be the most promising compartment for biomarker 
research in HIV-associated dementia.  Given the trafficking of the monocytes and 
macrophages and their important role in the pathogenesis of HAND, the blood 
compartment may be more informative and also more accessible (McGuire 2009). 
 
Dementia remains one of the most feared complications of HIV and it continues to pose a 




The development of cART has significantly altered the nature of HIV-associated cognitive 
disorders although they continue to be a major clinical problem among HIV-infected 
individuals (Grant 2008; Sacktor et al. 2002).  The incidence of HAD has decreased but 
the milder forms of neurocognitive impairment remain prevalent (Nath et al. 2008).  
However, because of the increased numbers of PLWHA and on cART, the prevalence of 
HAD is actually rising (McArthur 2004).  The clinical presentation of HAD has also 
changed in the cART era (Brew 2004).  Cysique and colleagues compared the prevalence 
and patterns of neuropsychological impairment in pre- and post-cART cohorts in Australia 
and found no significant differences between the prevalence of impairment between the 
two groups.  They did, however, find a difference in the pattern of neuropsychological 
impairment in the post-cART group.  There was an improvement in attention, verbal 
fluency and visuoconstruction deficits, but learning efficiency and complex attention ability 
seemed to have deteriorated.  It appears that the subcortical features that were previously 
thought to be characteristic are less prominent now (Cysique et al. 2004).  In general, 
cART does improve neuropsychological function and this improvement is noted in a 
number of different cognitive domains.  Improvement is, however, neither full nor 
universal.  It is possible that remaining deficits reflect a loss of cortical neurones and that 
the reversible deficits reflect damage to white matter.  It is also possible that cART has a 
greater treatment impact on the more severe forms of HAND than on the milder forms 
(Joska et al. 2010c).   
 
Several mechanisms to explain neuropsychological improvement have been proposed in 
the literature (Cysique et al. 2009) (Figure 2.9).  It is possible that systemic treatment 
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alone is enough to have a beneficial effect on the CNS (Sinclair et al. 2008).  ART 
markedly improves morbidity and mortality in HIV by reducing plasma viral load to 
undetectable levels and restoring immune function (Letendre et al. 2004).  These lower 
viral loads and improvement in CD4 counts and immune function may benefit the CNS by 
reducing the number of circulating activated monocytes, leading to a reduction in their 
migration into the brain.  This decreases the load of viral proteins that the brain is exposed 
to as well as reducing levels of immune activation, neuroinflammation and the production 
of neurotoxic chemicals (Liner II et al. 2008; Sinclair et al. 2008; McArthur et al. 2004; 
Brew 2004).  Alternatively it is also possible that ART improves neurological function by 
acting locally within the brain.  For this to be effective, we need to use antiretroviral drugs 
with good CNS penetration.  The effect of ART within the brain may be the key to 
maintaining a lower viral load in the CSF and decreasing local immune activation and 




Figure 2.9 Model of CSF HIV-1 infection and its relation to immune activation and 
treatment responses. 
 (Sinclair et al. 2008) 
 
Neurological improvement due to cART remains variable.  In some individuals 
improvement occurs within the first few weeks after initiation of cART, while in the majority 
of individuals improvement may occur after up to a year on treatment (Joska et al. 2010c).  
 37 
The early cognitive response due to cART might be associated with a greater degree of 
baseline impairment and neuroinflammation as well as with good systemic viral 
suppression on cART (Wojna and Nath 2006).  Joska et al reported on the impact of cART 
in a prospective study in South Africa and found that individuals most impaired at baseline 
(i.e. those with low CD4 counts, high viral loads, and high levels of inflammation) were 
more likely to improve at follow-up after one year than those who were less impaired 




Figure 2.10 Change in Global Deficit Score at baseline and one year of participants 
initiating cART across groups of severity at baseline. 
 (Joska et al. 2012) 
 
Various other treatment modalities have been investigated, but to date these have not 
been proven to be successful options.  Early initiation of an effective cART regime remains 
the gold standard in treating HAND, and needs to be combined with a focus on controlling 







The effective use of cART is associated with a significant reduction in the disease burden 
of HAD.  People who initiate cART before they have severe immunosuppression and who 
achieve plasma and CSF viral suppression after starting treatment with CSF penetrating 
regimens benefit the most from cART (Letendre et al. 2004; Sacktor et al. 2003).  Prior to 
the introduction of cART, HIV-dementia usually followed a progressive course over 3 to 9 
months, leading to severe neurological deficits and eventually death  (Navia et al. 1986).  
With cART, survival rates have improved from a mean of 5 months to 38.5 months (Dore 
et al. 2003).  In South Africa, with the largest HIV epidemic in the world despite one of the 
biggest anti-retroviral rollout programmes, people with HIV-infection still enter treatment 
late or not at all.  Given that more than 20% of individuals in primary care in the Western 
Cape province of South Africa have HIV-associated cognitive impairment, there are 
significant implications for care (Joska et al. 2011; Joska et al. 2010b). 
 
It is interesting that not all HIV-positive individuals develop cognitive impairment and a 
variety of host and viral factors have been identified as associated with an increased risk 
of developing HAND.  These factors will be discussed in the next section with specific 





















Figure 2.11 Risk factors for HIV-associated neurocognitive disorders. 
(Alfahad and Nath 2013) 
 
Of the various clinical factors associated with HAND, some are especially important in the 
South African setting.  HAND has been consistently associated with low CD4 cell count 
and late stage disease (Heaton et al. 2010).  This is also the case in South Africa where 
the HIV epidemic is greatest and access to cART is still limited (Joska et al. 2011).  
Methamphetamine abuse is a major problem in South Africa and not only increases HIV 
risk behaviour, but has also been associated with increased risk of neuropsychological 
impairment and both pathological and radiological evidence of neurodegeneration (Hult et 
al. 2008; PlüDdemann et al. 2008; Langford et al. 2003).  
 
In South Africa, the majority of HIV-infected people attending clinics are women and many 
of them present with late stage disease.  Depression is a common co-morbidity with HAND 
and women are more prone to suffer from depression (Kessler et al. 2005).   
 
Several pathological conditions as well as physiological ageing may be associated with 
cognitive, neurological or psychiatric dysfunction and may potentially confound the 
diagnosis of HAND.  There is substantial evidence that advancing age (> 50 years) may 
make PLWHA vulnerable to developing HAND (Valcour et al. 2004b).  Some studies 
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attribute this to the ageing brain itself or to the duration of HIV disease (Brew et al. 2009).  
Neuropathological similarities exist between Alzheimer’s disease (AD) and HAND (Green 
et al. 2005; Esiri et al. 1998).   
 
Individuals may also be genetically more susceptible to developing cognitive problems  
(Schouten et al. 2011).  Host genetic factors include the ε4 allele of APOE that has been 
associated with an increased risk of HAD especially in the elderly (Valcour et al. 2004a).  
Polymorphisms in cytokine and chemokine pathways and innate immune responses have 
been implicated in HIV-associated neurocognitive dysfunction (Singh et al. 2004).  Gene 
variants in inflammatory proteins may modulate neurodegenerative diseases such as AD 
and HAND in which neuroinflammation plays a significant role in the pathogenesis 
(Jayadev and Garden 2009).   
 
Viral genetic factors, such as Tat derived from different viral clades, may also affect 
neurotoxicity, although it is not yet evident whether viral clade does have an important 
influence on acquiring HAND (Mishra et al. 2008; Rao et al. 2008).   
It is thus clear that there are various underlying pathophysiological mechanisms that can 
impact on the development and clinical picture of HAND.  Thus the entity of HAND has to 




2.4 Viral clade 
 
HIV-1 strains are grouped according to the sites they prefer to replicate in.  T-tropic 
viruses prefer to replicate in T lymphocytes and M-tropic viruses in macrophages.  M-
tropic HIV-1 is most commonly identified within the brain (McArthur et al. 2010).  HIV-1 
Group M has further been divided into 10 subtypes labelled A to J.  These HIV-1 subtypes, 
also called clades, are genetically linked viral strains that are, in some cases, also linked 
geographically or epidemiologically.  HIV-1 clades display an uneven global distribution 
with the most prevalent subtypes being A, B, and C (see Figure 2.12) (Taylor et al. 2008; 
Mishra et al. 2008; Hemelaar et al. 2006).  Sub-Saharan Africa is the region most affected 
by the HIV epidemic and here HIV-1 clade C infection is most common, accounting for 
around 50% of infections worldwide (Buonaguro et al. 2007).   
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Figure 2.12 Current global distribution of HIV-1 subtypes and recombinant forms. 
 (Taylor et al. 2008) 
 
Viral subtypes may differ in their characteristics and their interaction with the human host, 
which may influence pathogenesis, transmission, diagnosis, disease progression, and 
treatment of HIV (Taylor et al. 2008; Hemelaar et al. 2006; Kanki et al. 1999).  The 
majority of HIV research has been conducted in populations of European descent – 
Europe, Australia and the Americas – where HIV infection is almost exclusively due to 
subtype B.  These research findings are responsible for much of our current understanding 
of the disease progression of HIV-1 and may not be generalizable to HIV clades and 
human populations in sub-Saharan Africa or other developing countries where different 
clades predominate (Ellis et al. 2009; McCutchan 2006; Kanki et al. 1999).   
 
Previous laboratory studies have showed that clade-specific differences in 
neuropathogenicity exist among clade B and clade C infected subjects with neurological 
deficits being more common in clade B than in clade C prevalent areas (Mishra et al. 
2008; Rao et al. 2008).  The exact mechanisms underlying these differences in 
neuropathogenesis by both subtypes remain unclear, but have been ascribed to variations 
in the neurotoxic region of the regulatory viral protein, Tat (McArthur et al. 2010; Gandhi et 
al. 2009).  Clade C has been reported as less neurovirulent than clade B resulting in 
milder cognitive dysfunction (Mishra et al. 2008).  Gandhi et al demonstrated lower levels 
of pro-inflammatory and higher levels of anti-inflammatory cytokine expression caused by 
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Tat C compared with Tat B, which might contribute to the lower neuropathogenicity of 
clade C (Gandhi et al. 2009).   
 
Recent publications have reported conflicting results relating to the clade C risk for 
acquiring HAND.  A study in Ethiopia did not find impairment on the IHDS of HIV-positive 
cART-naïve patients infected with clade C when compared to HIV-negative controls  
(Clifford et al. 2007).  In contrast, the Australian Pacific NeuroAIDS Consortium found 
substantial deficits in cognitive and motor function in subjects infected with clade C HIV-1  
(Wright et al. 2008).  A study in China found HAND deficits that were comparable with 
those reported in western countries with mostly clade B infection (Heaton et al. 2008).  
Similarly, a study of HIV-positive, cART-naïve subjects in South Africa where clade C 
predominates, found the prevalence of MND and HAD to be 42.4 and 25.4% respectively  
(Joska et al. 2010d).  These, and several other, studies in distinct clade C cohorts 




2.5 Apolipoprotein E 
 
Apolipoprotein E (apoE) is a plasma protein originally studied for its role in lipid 
metabolism and transport of lipids among various cells of the body (Weisgraber 1994; 
Mahley 1988).  ApoE is expressed in three common isoforms designated apoE2, apoE3 
and apoE4.  The gene for apoE is located on human chromosome 19 within the same 
genomic region that has previously been associated with late-onset familial AD (Mahley 
and Rall Jr 2000; Poirier et al. 1993).  The apoE isoforms have been shown to play key 
roles in other biological processes not related to lipid metabolism such as modulating 
innate and acquired immune responses in vitro and in vivo, and being a risk factor for AD  
(Burt et al. 2008; Laskowitz et al. 2001; Poirier et al. 1993).  ApoE is the main 
apolipoprotein produced by astrocytes and microglia in the CNS and apoE has been 
shown to play a role in the CNS response to chronic HIV infection (Kuhlmann et al. 2010b; 
Urosevic and Martins 2008; Lynch et al. 2003; Saura et al. 2003).  
 
The frequency of the three alleles – epsilon-2 (ε2), epsilon-3 (ε3), and epsilon-4 (ε4) – of 
the apoE gene (APOE) vary substantially between different ethnicities around the world, in 
particular between individuals of European and African descent (Gerdes 2003).  APOE ε3 
 43 
is said to be the most common in human populations everywhere, but high APOE ε4 
frequencies have been reported in African populations (Eichner et al. 2002; Zekraoui et al. 
1997).  Sandholzer found an allelic frequency of 37% for the Khoi San (“Bushmen”) of 
southern Africa (Sandholzer et al. 1995).  The higher frequency of ε4 in individuals of 
African ethnicity may have implications for the rate of occurrence of neurodegenerative 
conditions in the southern African setting (Joska et al. 2010a). 
 
 
Figure 2.13 APOE allele frequencies in various African populations.  In the pie charts, 
solid sections refer to the APOE ε2 allele, vertically ruled sections to the 
APOE ε3 allele, and stippled sections to the APOE ε4 allele. 
 (Zekraoui et al. 1997) 
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APOE ε4 has been identified as a risk factor for AD and has also been investigated as a 
host risk factor for the development of HAND (Saunders et al. 1993a).  There are 
similarities between neurodegeneration in AD and that of HAD with AIDS patients possibly 
having an increased risk for developing amyloid plaques in the cerebral cortex (Esiri et al. 
1998).   
  
Multiple mechanisms of apoE modulation of neurodegeneration have been proposed 
(Figure 2.14):   
 
Figure 2.14 The relationship between APOE ε4, systemic infection, CNS inflammation, 
neurodegeneration and cognitive impairment in HIV-1 infection. 
 
Chronic neuroinflammation is a well-established characteristic of HAND as well as of AD  
(Smits et al. 2000).  A study done by Harry et al. suggested a regulatory role for apoE in 
maintaining a critical balance between various pro-inflammatory cytokines.  An age-
dependent increase in the expression of pro-inflammatory cytokines TNF-α and IL-6 in the 
blood after LPS injection was observed in APOE ε4 transgenic mice (Lynch et al. 2003; 
Harry et al. 2000).  Vitek and colleagues demonstrated a more pro-inflammatory 
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phenotype that included altered cell morphology and increased production of cytoactive 
factors in microglia derived from APOE ε4 transgenic mice compared to ε3 transgenic 
mice (Vitek et al. 2009).  ApoE4 was also found to be less effective than apoE2 and apoE3 
at suppressing microglial activation and brain inflammation (Laskowitz et al. 2001; Barger 
et al. 1995).  Cutler and colleagues found elevated levels of sphingomyelin, ceramide and 
cholesterol in the brains of HAD patients with the ε4 allele compared to those with the ε3 
allele (Cutler et al. 2004).  This disturbance in sphingolipid metabolism may make 
neurones more vulnerable to injury through oxidative stress, and may, therefore, play a 
role in the initiation and progression of dementia in HIV-1 infected patients with the APOE 
ε4 genotype (Cutler et al. 2004; Haughey et al. 2004).  Additionally, apoE3 has been 
shown to protect neurones against HIV-1 Tat toxicity in vitro while apoE4 does not have 
any protective properties against Tat-induced oxidative effects (Pocernich et al. 2004).  In 
summary, it seems that apoE plays an important role in modifying both systemic and brain 
inflammatory responses.  These effects seem to be specific to the ε4 allele as it is less 
effective than ε3 at down-regulating the brain’s inflammatory response and has also been 
associated with an increased expression of pro-inflammatory cytokines in vivo, both 
peripherally and centrally.  The apoE4 isoform has also been shown to affect lipid and 
sterol metabolism in the brain, increasing the susceptibility of neurones to oxidative insults. 
 
Another mechanism by which apoE may influence the risk of acquiring HAND is through 
directly affecting the dynamics of HIV infectivity (Jayadev and Garden 2009).  Burt et al. 
found the presence of the ε3 allele to be associated with a slower HIV disease 
progression.  The presence of two ε4 alleles was, however, associated with an 
accelerated HIV disease course.  ApoE4 also predisposes cells to a significantly higher 
rate of HIV cell infection in vitro by facilitating a greater frequency of fusion events than 
apoE3 (Burt et al. 2008).  Carrying the ε4 allele has been associated with an increased 
steady-state viral load (Kuhlmann et al. 2010a).  In summary, the available evidence 
indicates that the presence of the ε4 allele has detrimental effects on the course of HIV 
infection through accelerated virus entry, higher viral loads and faster disease progression. 
 
Published clinical reports relating APOE ε4 to HAD have produced conflicting results.  
Corder and colleagues reported HAD as being twice as prevalent in carriers of the ε4 
allele compared with non-carriers.  Subjects with the ε4 allele had excess dementia, 
demonstrated little improvement over a series of neuropsychological tests and also had 
slower mental speed than subjects with the ε3 allele (Corder et al. 1998).  Valcour et al 
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observed that, after controlling for age and diabetes status, the presence of an APOE ε4 
allele was associated with a threefold independent increase in the risk for HAD in older 
(i.e. ≥ 50 years of age) HIV-positive individuals.  No increased risk related to APOE ε4 
was, however, demonstrated in younger participants in the group (Valcour et al. 2004b).  
In a HIV-infected Chinese cohort, the ε4 allele was found to be present in a greater 
proportion of cognitively impaired people than those with other apoE isoforms (Spector et 
al. 2010).   
 
In contrast, several studies have failed to demonstrate a relationship between APOE ε4 
and HAD.  Although the ε4 allele was associated with an accelerated HIV disease course, 
Burt et al. did not detect an association between APOE genotype and the rate of 
progression to HAD (Burt et al. 2008).  Other studies also did not find statistically 
significant relationships between apoE genotypes and the risk of HAND (Morgan et al. 
2013; Dunlop et al. 1997).  The first Southern African study to evaluate the relationship 
between apoE genotype and HAND was done by Joska et al. in 2010.  This group also 
found no differences in the allelic distributions of apoE across the different HAND 
categories.  In fact, they noted a significantly lower frequency of the ε4 allele in adults with 
HAD compared to those without HAD (Joska et al. 2010a). 
 
In summary, the apoE allelic variants occur with different frequencies across different 
populations around the world.  The ε4 allele is thought to be the most common in African 
populations, and particularly in southern Africa where a high prevalence of ε4 was 
reported amongst the native Khoi San population.  Multiple mechanisms of apoE 
modulation of neurodegeneration in HIV-positive individuals have been proposed.  Most 
studies of apoE have been conducted in countries where HIV-1 clade B is predominant, 
and results have been controversial.  Large prospective cohort studies of HIV-1 clade C-
positive subjects of African descent are needed to further examine the relationship 





HIV-1 enters the CNS early after infection.  A low-grade inflammatory response 
(neuroinflammation) is initiated as a result, and this can lead to neurodegeneration and 
cognitive impairment in up to 50% of HIV-positive individuals.  The spectrum of HAND 
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ranges from mild impairment to severe dementia.  Repeated or chronic systemic infections 
may enhance neuroinflammation and consequently drive neurodegeneration through 
signalling from the peripheral blood to the CNS.  The widespread use of cART has 
significantly altered the nature of HAND, specifically decreasing the incidence of dementia 
due to HIV.  The less severe forms of HAND, however, remain common.  Generally the 
initiation of cART improves neuropsychological function, but this improvement is neither 
full nor universal.  Not all HIV-positive individuals develop HAND, and a variety of host and 
viral factors have been associated with an increased risk of developing HAND.  Of 
particular importance in the South African setting is viral clade and apoE genotype.  HIV-1 
clade C predominates in southern Africa and has been associated with a potentially higher 
risk for moderate-to-severe HAND complications.  The ε4 allele of APOE is prevalent in 
African populations and in Southern Africa, and has been associated with an accelerated 
HIV disease progression and an increased risk of developing HAND. 
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CHAPTER 3: AIMS AND HYPOTHESES 
 
AIMS  
This study aims to define the role of systemic inflammation in the pathogenesis of HAND 
as well as to determine why some people with HIV develop neurocognitive impairment 
while others do not.  The study will provide information about risk or associative factors in 
an attempt to identify patients at risk for developing HIV-associated dementia.  
Furthermore it will aim to identify those patients expected to have a poorer neurocognitive 




• We shall measure levels of pro-inflammatory and anti-inflammatory cytokines in 




• We shall determine whether initial cytokine profiles predict improvement in 
cognitive scores as a response to cART, by comparing cognitive scores at 
baseline with follow-up cognitive scores after at least 9 months on cART. 
• We shall determine whether the presence of the APOE ε4 allele is associated 
with increased systemic inflammation and higher levels of pro-inflammatory 
cytokines compared with APOE ε2 or ε3. 
• We shall determine whether the presence of APOE ε4 is associated with worse 
cognitive impairment at baseline, compared with APOE ε2 or ε3. 
• Potential confounding effects (age, education, CD4 count) shall be taken into 




In the initial cross-sectional analysis of cART-naïve participants, a predominantly pro-
inflammatory cytokine profile in the peripheral blood will correlate with more severe 
cognitive impairment.  Conversely, better cognition will be associated with a predominantly 
anti-inflammatory cytokine profile.   
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That is, a predominance of pro-inflammatory cytokines will be associated with greater 
cognitive impairment whereas more anti-inflammatory cytokines will be associated with 
less cognitive impairment. 
 
The potential confounding effects of disease severity, as represented by the CD4 count, 
will be considered in testing this hypothesis. 
 
Hypothesis 2 
In the initial cross-sectional analysis, the presence of the ε4 allele of APOE will be 
associated with increased levels of systemic inflammation (higher levels of pro-
inflammatory cytokines) compared with the presence of the ε2 or ε3 alleles. 
 
In other words, the presence of the ε4 allele will be associated with higher levels of pro-
inflammatory cytokines.  Conversely, the absence of the ε4 allele will be associated with 
lower levels of pro-inflammatory cytokines. 
  
Hypothesis 3 
In the initial cross-sectional analysis, individuals in possession of the ε4 allele of the APOE 
gene will have greater cognitive impairment than those with the ε2 or ε3 alleles. 
 
That is, the presence of the ε4 allele will be associated with worse cognitive function.  




Participants with an initial pro-inflammatory cytokine profile at baseline will respond better 
to cART in terms of cognitive function than those with an initial anti-inflammatory profile. 
 
That is, a predominantly pro-inflammatory profile will be associated with greater 
improvement in cognitive function, while a predominantly anti-inflammatory profile will be 




CHAPTER 4: METHODS 
 
In 2007 a collaborative research programme was initiated by the Department of Medicine 
(Division of Neurology) and the Department of Psychiatry at UCT.  The aim of this project 
was to investigate the neurocognitive disorders found in young adults with HIV/AIDS 
commencing anti-retroviral treatment in the Western Cape of South Africa.   
 
My research project forms part of this larger study and is a cross-sectional, correlative 
analysis with a longitudinal component.  For my data analysis I utilized the participant 
information that was collected at baseline and follow-up visits, in the existing study prior to 
the start of my project.  Additionally, for my laboratory analysis, I used frozen serum 
samples that were collected at baseline and stored at -80°C.  APOE genotyping was also 





Research nurses from voluntary counselling and testing (VCT) clinics at Khayelithsa Site 
C, Woodstock Community Health Care Centre, and Mitchells Plain Community Health 
Care Centre in the Cape Town metropolitan area were responsible for screening and 
recruitment of the study participants.  Recruitment commenced in February 2008 and 
continued until August 2009.  These participants were all between the ages of 18 and 35 
years old, HIV-positive and cART naïve, but in the pre-treatment phase of counselling to 
start cART. 
 
In the larger original study 167 participants of the 283 participants that were screened 
completed baseline assessments.  Reasons for not attending the full assessment 
included: financial constraints, the inability to leave work and travel in and out of Cape 
Town.  Of the 167 baseline participants, 109 participants completed follow-up cognitive 
assessments after one year.  Of the 109 follow-up participants, 82 were known to have 
started cART and 22 were known not to have started cART.   
 
93 HIV-negative age-matched controls were recruited by invitation from the same VCT 
clinics.  These control participants underwent the full neuropsychological battery to assess 
their cognitive function in order to create a set of “normal” scores for each test.  This 
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allowed for the calculation of a “normal” population-specific mean and standard deviation 
for each test.  These values were used to calculate standard scores (Z and T scores) for 
each HIV-positive participant being tested by the same neuropsychological battery.  
 
From the group of 167 baseline participants who also met inclusion criteria for my study, I 
was able to randomly select a sample of 114 participants for the cross-sectional 
component of my study.  Of the 114, a group of 40 subjects met the inclusion criteria and 
were used for the longitudinal part of my study.  I did not include an HIV-negative control 
group because I was primarily interested in comparing inflammation and cognitive 
impairment within a group of HIV-positive patients.    
 
4.1.2 Inclusion criteria 
 
Original study: 
• Young adults between the ages of 18 and 35 years.  This age range was 
chosen to limit the confounding effect of age and age-related neurodegeneration 
or cerebrovascular disease 
• A recent positive diagnosis of HIV infection made within the last 6 months, 
including initial and confirmatory tests 
• No previous use of antiretroviral medications (cART-naïve) 
• Qualification for, and enrolment into, an antiretroviral treatment programme with 
routine follow-up via this local rollout clinic 
• At least 7 years of formal education 
 
This study: 
• Inclusion criteria for original study 
• Complete data (cognitive scores and CD4 count) 
• Available serum samples for cytokine analysis 
• At follow-up, on cART for at least 9 months to limit immune reconstitution 
inflammatory syndrome (IRIS) as a possible cause for symptoms 
 




To diagnose HAND it is necessary to exclude other potential causes of cognitive 
impairment, therefore subjects with the following conditions were excluded: 
• Presence of uncontrolled general medical conditions such as diabetes mellitus, 
epilepsy, and active tuberculosis requiring admission or second-line treatment 
• Presence of an identified central nervous system neurological condition such as 
lymphoma, untreated neurosyphilis, and cryptococcal infection.  Those who 
previously had such conditions and were deemed to have been fully treated 
were eligible for inclusion. 
• History of severe mental illness (psychotic disorder or active major depression) 
• Abuse of alcohol or other psycho-active substances within the preceding three 
months (current substance abuse / dependence) 
• History of head injury with loss of consciousness of >30 minutes duration, 
and/or requiring overnight admission to hospital 
• Participants who for any reason, could not undergo the full assessment 
including the blood tests and neuro-imaging studies 
• Participants who refused to sign informed consent 
  
This study: 
• Exclusion criteria for original study 
• Incomplete data (cognitive scores) 
• No serum available 
• At follow-up on cART for less than 9 months 
 
4.1.4 Study design 
 
The larger, original study was designed as a prospective controlled analytical study. 
 
My component of this larger study is a cross-sectional correlative analysis with a 
longitudinal component. 
 
In the cross-sectional part of the study, the levels of four selected pro- and anti- 
inflammatory cytokines in the peripheral blood of HIV-positive participants were measured 
and correlated with their cognitive function as assessed at baseline before starting cART.   
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I also used the apolipoprotein E genotype data available for all participants to investigate 
the relationships between the ε4 allele, systemic inflammation (concentrations of 
inflammatory cytokines) and cognitive impairment. 
 
In the longitudinal part of the study, I compared the cognitive scores as assessed at follow-
up after at least 9 months of cART therapy, with the baseline (pre-cART) cognitive 
assessment and cytokine profile to determine whether the baseline cytokine profile could 
predict subsequent changes in cognition on cART.  
 
4.1.5 Instruments and measures 
 
A. Screening assessments 
 
At the screening clinics, patients completed the following questionnaires that were used to 
identify any conditions that would exclude them from the study: 
• The Mini International Neuropsychiatric Interview (MINI): To exclude those with a 
history of severe mental illness (Sheehan et al. 1998); 
• The Centers for Epidemiological Study-Depression Scale: To exclude participants 
with active major depression (Myers and Weissman 1980); 
• The Alcohol Use Disorders Identification Test (AUDIT): To identify participants with 
a history of recent substance abuse (Saunders et al. 1993b) 
 
B. Baseline assessments 
 
Baseline assessments involved a clinical examination, cognitive/neuropsychological test 
battery and the collection of functional, quality of life and socio-demographic data (age, 
weight, height, gender and home language).  A total of 30 millilitres of blood was also 
collected for routine laboratory tests, APOE genotyping and cytokine analysis. 
 
Clinical evaluation 
The clinical evaluation involved a general physical and a neurological examination.  The 
neurological investigation focussed on detecting signs of peripheral neuropathy (visual 
analogue scale and assessment of vibration sense), an assessment of motor tone and 
power, involuntary movements, primitive reflexes and a timed gait test for motor slowing. 
An assessment of cognition was performed using the International HIV dementia scale 
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IHDS, a screening tool for HIV-associated dementia (Power et al. 1995).  The latter has 
also been validated for use in developing countries (Sacktor et al. 2005).  In addition, the 
Mini Mental State Examination (MMSE) was used as a screening tool for cognitive 
impairment (Folstein et al. 1975).  Neurological findings were used to calculate a 
neurological raw score that was used to determine HAND category (Joska et al. 2010d). 
 
Special investigations 
Blood specimens for determining full blood count, kidney and liver function tests, C-
reactive protein, calcium, magnesium, phosphate, total protein, glucose, folate, vitamin 
B12 and iron studies were collected at the first clinic visit.  Lowest pre-treatment CD4 cell 
count (nadir CD4) and viral load data were obtained from the clinic records at the 
recruitment sites.  Blood specimens were also used for APOE genotyping and freshly spun 
serum stored for measurement of inflammatory cytokines.  
  
DNA was extracted from whole blood samples and APOE genotyping was performed at 
the Department of Chemical Pathology (UCT Medical School) using the restriction enzyme 
digestion method described by Hixon (Hixson and Vernier 1990).   
 
Whole blood samples for inflammatory markers were centrifuged at 4000rpm for 10 
minutes immediately after collection and the serum supernatant was aspirated, aliquotted, 
and stored at -80°C for subsequent analyses.   
 
Neuro-imaging was performed using MRI at the Cape Universities Brain Imaging Centre 
(CUBIC) at Stellenbosch University Medical School in collaboration with the medical 
imaging unit at UCT.  The purpose of neuro-imaging for my study was primarily to exclude 
intracranial or mass lesions. 
 
Cognitive tests and neuropsychological assessment 
The domains most affected by HAND are attention, learning and memory, motor function, 
psychomotor speed, executive function, psychomotor speed, executive function and 
language (Power et al. 2009; McArthur et al. 2005).  All participants underwent a battery of 
cognitive tests.  The tests were translated into Xhosa and Afrikaans and validated by back-
translation into English.  Changes to word lists were made to reflect local language and 
idioms.  The test battery was selected so that the tests represented the domains typically 
affected by HIV (Butters et al. 1990).  These specific tests were also commonly used in 
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international settings, and thus made our findings comparable.  The selected battery was 
based on that used by the San Diego HIV Neurobehavioral Research Center (HNRC) 
(located at the University of California in San Diego) (Carey et al. 2004b).  The battery 
comprised the following tests: 
• Attention (Mental Alteration Test and Mental Control Test) 
• Learning and memory (Hopkins Verbal Learning Test and Brief Visuospatial 
Memory Test) 
• Motor (Finger Tapping and Grooved Peg Board – dominant and non-dominant 
hands) 
• Psychomotor speed (Trail Making part A, Color Trails 1 and Digit Symbol Coding) 
• Executive function (Color Trails 2, Stroop Color Word test, Wisconsin Card-sorting 
Test and Rey Complex Figure) 
• Language (Category fluency animals and Category fluency fruit and vegetables) 
 
Table 4-1 further explains how the tests are done and the aspect of cognitive function 
being tested. 
 
Cognitive tests according to domain 
a) Attention 
Mental Alternation Test (MAT) 
(Jones et al. 1993) 
Participants are asked to count to 20 and 
then to recite the alphabet.  Thereafter they 
must recite both at the same time, in 
ascending sequence and alternating 
between numbers and letters, in a set time 
period. 
• Tests sequencing ability and switching 
between categories 
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Weschler Memory Scale III (Mental Control 
Test) 
(Wechsler 1997a) 
Participants must recite known sequences 
such as the numbers 1-20, days of the 
week, or months of the year.  The task is 
then repeated with the sequence in reverse.  
The tests are timed. 
b) Learning and Memory 
The Hopkins Verbal Learning Test (HVLT) 
(Brandt 1991) 
3 trials of recall (immediate and 15 min 
delayed) of a 12-item, semantically 
categorized list.  This is followed by yes/no 
recognition of the words within a longer list 
of other words that are similar. 
• A brief assessment of verbal learning 
and memory based on recognition and 
recall; total learning 
The Brief Visuospatial Memory Test (BMVT) 
(Benedict 1997) 
Participants are shown 6 figures for 10 sec 
each and are then required to replicate 
exact copies, immediately and at 25 min 
delayed recall.  They are also asked to 
identify the 6 figures from a list of 12 similar 
figures. 
• Tests visuospatial and recall ability; total 
learning 
c) Motor function 
Finger Tapping Test 
(Halstead 1947) 
 
Participants must tap on a key counter 
using the index finger of the dominant hand 
for 10 sec.  This is repeated until 5 
consecutive trials within 5 taps of each 
other, or a total of 14 trials are obtained.  
The test is then repeated with the non-
dominant hand. 
• Tests motor speed and motor control 
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Grooved Pegboard Test 
(Klove 1963) 
Participants are required to place 25 small 
metal pegs into 25 holes on a metal board.  
All pegs are similar with a ridge along one 
side, which corresponds to a randomly 
positioned slot in each hole on the board.  
Each peg must, therefore, be rotated to 
match the slot on the hole before it will fit. 
Pegs should be placed as fast as possible, 
first with dominant and then non-dominant 
hand. 
• Tests manual dexterity, co-ordination 
and motor speed for dominant and non-
dominant hands 
d) Psychomotor Speed 
Trail Making Test A 
(Reitan and Davison 1974) 
The participant is presented with a series of 
randomly arranged circles, each of which 
contains a different number from 1-25. The 
task is to connect the circles in ascending 
order as fast as possible. 
• Tests visual attention, task switching 
and mental flexibility 
Color Trails I 
(D'Elia 1996) 
The participant is presented with a series of 
randomly arranged circles, each with a 
number from 1-25.  Circles alternate in 
colour and the task is to connect the 
consecutive numbers in an ascending 
sequence, which also implies alternating 
colours. 
• Tests visual attention, ability to switch 
between tasks and mental flexibility 
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Wechsler Adult Intelligence Scale, 3rd 
Edition – WAIS III (Digit Symbol Coding) 
(Wechsler 1997b) 
 
Participants are presented with paired digits 
and symbols.  A list of digits is then given 
and the participant must write the 
appropriate symbol next to each digit as fast 
as possible. 
• Assesses processing speed 
e) Executive Function 
Color Trails 2 
(D'Elia 1996) 
The test is made up of colour-number pairs 
and the colours should be alternated when 
chronologically connecting the numbers. 
• Tests visual attention, ability to switch 
between tasks and mental flexibility 
Stroop Color Word Test (SCWT) 
(Stroop 1935) 
The participant is first asked to read the 
names of colours printed in black and white.  
Next, the participant is presented with a 
page where the names of colours are 
printed in conflicting colours (e.g. BLUE 
written in green ink).  The test is to name 
the colour that they see and not read the 
name that is written. 
• Tests executive function, processing 
speed, selective attention and cognitive 
flexibility 
Wisconsin Card Sorting Test (WCST) 
(Heaton et al. 1993) 
This test uses cards with different shapes, 
colours and quantities.  Participants must 
match another set of cards to the first cards 
without being told how the cards are to be 
matched (according to shape, colour or 
quantity).  They are only informed when 
cards are correctly or incorrectly matched.  
This task tests the ability to form strategies, 
to shift strategies and to learn. 
• Tests executive function, attention, set-
shifting, modulating impulsive behaviour 
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The Rey Osterrieth Complex Figure (RCF) 
(Corwin and Bylsma 1993; Rey and 
Osterrieth 1993) 
Participants are presented with a complex 
figure, using different coloured lines that 
they must first copy and then draw from 
memory at 3 and 30 min after the initial 
copying task. 
• Tests visuospatial ability, attention, 
planning and working memory 
f) Language 
Category fluency animals and fruit & 
vegetables 
(Butters et al. 1987) 
Participants must generate orally as many 
different kinds of animals, fruits and veg as 
possible within a given time limit (1 min for 
each category). 
• Tests language fluency 
 
Table 4-1 Neuropsychological test battery 
 
Neuropsychological interviews were performed to assess quality of life and functioning in 
activities of daily living: 
• The Patient’s Assessment of Own Functioning (PAOFI) (Chelune et al. 1986) 
• Quality of Life Enjoyment and Satisfaction Scale (QLESQ) (Endicott et al. 1993) 
These instruments were also translated into Xhosa and Afrikaans and the translation was 
validated through back translation into the first language.  Ratings on the PAOFI were 
used to generate a rank score for functional impairment.  This rank score was also used to 
determine HAND category. 
 
Due to the lack of validated normative data for our population, z-scores were calculated 
from the HIV-negative control data and then used to determine the degree of impairment. 
 
The neuropsychological test battery, together with the scores from the neuromedical 
assessment and the functional impairment scores were used to determine neurocognitive 
disorder status.  Based on these scores, participants with impairments were classified into 
one of the three HAND categories as described by Antinori and colleagues in 2007: (1) 
HIV-1-asymptomatic neurocognitive impairment (ANI), (2) HIV-1-associated mild 
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neurocognitive disorder (MND), and (3) HIV-1-associated dementia (HAD) (Antinori et al. 
2007) (Table 4-2 provides a summary of the revised criteria.) 
 





0 Normal cognition Normal Normal 
1 ANI 
Acquired impairment 
in at least 2 cognitive 
domains (<1SD) 





in at least 2 cognitive 
domains (<1SD) 
Interferes with daily 
functioning to at least 






in at least 2 domains, 
typically in multiple 
domains with at least 
2 domains with severe 
impairment (<2SD) 
Marked impact on 
daily functioning. 
 
Table 4-2 Summary of the research criteria for HAND   
 (Valcour et al. 2011) 
 
A Global Deficit Score (GDS) was also calculated for each participant as a quantitative 
measure of global cognitive deficits.  The raw data from the neuropsychological test 
battery were converted to demographically corrected, standard scores (t-scores) using the 
normative data from the control group.  The GDS is a useful way to summarize the results 
on neuropsychological testing and is calculated by converting the demographically 
corrected standard scores on individual neuropsychological tests to a deficit score ranging 
from 0 (no impairment) to 5 (severe impairment) – see Table 4.3 (Carey et al. 2004a; 




T scores Deficit Score Degree of impairment 
≥ 40 0 Normal 
39-35 1 Mild 
34-30 2 Mild-moderate 
29-25 3 Moderate 
24-20 4 Moderate-severe 
≤ 19 5 Severe 
 
Table 4-3 A conversion table for transforming T scores into deficit scores 
 (Carey et al. 2004b) 
 
An average GDS was then calculated for each participant with higher scores indicating 
greater impairment.  Based on these scores, participants were grouped into three GDS 
groups: non-impaired (GDS ≤ 0.25), mild-moderately impaired (0.25 < GDS ≤ 0.75), and 
severely impaired (GDS > 0.75).  These 3 groups were shown to correlate with the HAND 
categories of normal function, ANI, MND and HAD (Joska et al. 2012).  The GDS has 
shown good sensitivity in detecting milder neuropsychological impairment in patients with 
HIV (Heaton et al. 1995).  It is a useful tool for classifying cognitive impairment in HIV, as it 
does not require the use of functional assessments like the revised criteria for HAND.  The 
GDS is a more objective measure, because HIV-positive patients often visit healthcare 
centres alone, without someone to give collateral information.  The latter is problematic 
especially if the participant lacks insight (Valcour et al. 2011).  For these reasons, I 
decided to use the global deficit scores in my correlation analyses with inflammatory 
markers and apolipoprotein E. 
 
Cytokine measurement 
Serum samples for inflammatory markers were processed at the Centre for Proteomics 
and Genetic Research (CPGR) at the Institute for Infectious Diseases and Molecular 
Medicine (IIDMM) at the UCT Medical School.  These markers (analytes) included the pro-
inflammatory cytokines – IL-1β and TNF-α, and the anti-inflammatory cytokines – IL-10 
and TGF-β1.  These cytokines were selected because experimental and clinical studies 
have shown that their expression is rapidly inducible by an inflammatory insult to the CNS.  
It is also thought to be the balance between pro-and anti-inflammatory cytokines in the 
brain that may have a profound impact on neuronal function (Boche et al. 2003).  Cytokine 
analysis was done by simultaneous multi-analyte detection at the CPGR laboratory.  After 
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delivery to the CPGR laboratory the serum samples were thawed once on ice and then 
stored at 4°C until time of assay.  Each sample was assayed, in duplicate, according to the 
manufacturer’s instructions included in the assay kits.  
 
Assay Name Analytes 
Bioplex ProTM Assays 
Cytokine, Chemokine and Growth Factors 
BIO-RAD (www.bio-rad.com) 
TNF-α, IL-1β, and IL-10 
Fluorokine® MAP TGF-B 
Multiplex Kit 
R&D Systems (www.RnDSystems.com) 
TGF-β1 
 
Table 4-4 Assay kits used to determine cytokine profiles in serum samples 
 
The Bio-rad Bio-plex 200 analyzer – a dual laser, flow-based sorting and detection 
platform – was used for both the Bioplex Pro™ and Flourokine® MAP kits.  (The 
Fluorokine MAP multiplex kits are designed to use with a Luminex® or BioRad® BioPlex® 
analyser.) 
Multiplex cytokine assays allow researchers to simultaneously measure the levels of 
multiple cytokines in a single, and minimal volume (as little as 12.5 microlitres) sample of a 
matrix such as serum.  This can be done in just three to four hours. 
The Bio-Plex® suspension array system is built on the three core elements of xMAP 
technology: 
• Fluorescently dyed micro particles (also called beads), each with a distinct colour 
code to allow detection of individual analytes within a multiplex suspension. 
• Dedicated flow cytometer with two lasers and associated optics to measure the 
different molecules that are bound to the surface of the beads. 
• A high-speed digital signal processor that efficiently manages the fluorescence 
data. 
 
The principle of the assay is similar to that of a sandwich enzyme-linked immunoassay for 




Figure 4.1 Bio-Plex sandwich immunoassay 
From: Bio-Plex Pro™ Assays Cytokine, Chemokine, and Growth Factors Instruction Manual. Bio-
Rad Laboratories, Inc.  
 
Analyte-specific antibodies are pre-coated onto the fluorescently dyed and colour-coded 
beads (Figure 4.2 a).  The beads, standards and samples are then pipetted into wells and 
the immobilized antibodies bind the analytes of interest.  After a series of washes to 
remove unbound substances, a biotinylated detection antibody is added to each well to 
create a sandwich complex (Figure 4.2 b).  Following a wash to remove any unbound 
biotinylated antibody, streptavidin-phycoerythrin (streptavidrin-PE) conjugate is added to 
form the final detection complex (Figure 4.2 c).  Phycoerythrin serves as a fluorescent 
indicator, or reporter.  
 
Figure 4.2 Multiplex immunoassay technology 
From: http://www.bio-rad/evportal/en/ZA/LSR/Solutions/LUSM0E8UU/Multiplex-Immunoassays  
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A final wash removes unbound streptavidrin-PE and the micro particles are again 
suspended in buffer and read using the Bio-Plex 200 analyser.  When the multiplex assay 
suspension is drawn into the analyser, a red (635 nanometre) laser illuminates the 
fluorescent dyes within each bead and identifies which analyte is being detected.  At the 
same time a green (532 nanometre) laser stimulates the phycoerythrin to generate a 
reporter signal, which is detected by a photomultiplier tube.   
 
 
Figure 4.3 Flow cytometry-based analysis 
From: http://www.bio-rad/evportal/en/ZA/LSR/Solutions/LUSM0E8UU/Multiplex-Immunoassays 
A high-speed digital processor manages the data output and Bio-Plex Manager™ software 
presents the data as Median Fluorescence Intensity (MFI) as well as concentration 
(picogram/millilitre (pg/mL)).  The concentration of analyte bound to each bead is 
proportional to the phycoerythrin-derived report signal.  
 






The use of antibody microarray assays provides a reliable method for analysing profiles of 
inflammatory mediators with limited amounts of serum samples (Knight et al. 2004).  The 
majority of published studies have generally shown fairly good correlations between these 
assays and ELISAs for most cytokines tested (Ray et al. 2005; Kellar and Douglass 2003; 
Prabhakar et al. 2002; Chen et al. 1999).  The degree of correlation, however, varied 
widely and was mostly ascribed to differences in the antibodies that were used (Elshal and 
McCoy 2006).  Multiplex approaches may compromise the ability of such assays to 
accurately measure the actual levels of cytokines (Siawaya et al. 2008).  DuPont and 
colleagues examined the correlation of ELISA and multiplex bead assays for measuring 
the quantity of a variety of cytokines.  Although they demonstrated excellent correlations 
for seven cytokines, which included IL-1β, IL-10 and TNF-α, they found significant 
variation between the absolute cytokine concentrations determined by ELISA and the 
multiplex kits.  These differences were again ascribed to differences in antibody pairs and 
sample diluents that were used (dupont et al. 2005).  As an alternative to using a 
multiarray platform for cytokine quantitation, it can be used to look at relative change 
rather than absolute cytokine levels, with results being expressed as percentage change 
form a baseline level (Toedter et al. 2008). 
 
We elected to use multianalyte detection for our cytokine analysis, because it allowed us 
to use much smaller serum concentrations than we would have needed for standard 
ELISAs.  Because we were only interested in analysing four cytokines we trusted that the 
results of our analyses would be accurate and comparable, with less cross-reaction.  We 
also trust that the manufacturers’ kits have been optimized to eliminate or minimize any 
artefacts due to multiplexing, given rigorous adherence to the manufacturers’ protocols.  
The CPGR reported that manufacturer’s instructions for the Bio-Plex Pro™ Multiplex 
Cytokine Assay (IL-1β, TNF-α and IL-10) were followed without any deviation.  The 
manufacturer’s protocol for the Fluorokine® MAP TGF-β Multiplex Kit was followed, but an 
additional centrifugation step was included for all samples following activation and prior to 
performing the assay.  This centrifugation step, in a bench-top centrifuge (10000g for 5 
min), was necessary to remove precipitates that formed following activation.  Each of the 
plates used in our assay had an internal quality control, which consisted of the generation 
of a standard curve for each analyte using the reference cytokine concentrations supplied 
by the manufacturers.  All plates passed quality control.  Blank and negative control 




Upon completion of the assays, CPGR provided us with an analytical report depicting the 
study procedure that was followed as well as all results generated. 
 
4.1.6 Study procedure 
 
Patients attending the Khayelitsha site C, Woodstock and Mitchells Plain primary care 
ARV clinics were screened for inclusion and exclusion criteria by clinic staff.  Potential 
subjects were then properly screened by an investigator and enrolled into the study after 
giving written informed consent.  After the informed consent, subjects completed the self-
report questionnaires and were then referred to the Department of Psychiatry at Groote 
Schuur Hospital for a baseline assessment.  The baseline assessment included the 
collection of socio-demographic data, anthropometric measurements, a clinical including 
neurological assessment, and the neuropsychological test battery.  Blood was taken for 
baseline laboratory tests and was also stored for genetic and proteomic investigations.  
APOE genotyping was performed at the Department of Chemical Pathology (UCT Medical 
School).  Brain imaging was performed at the Cape Universities Brain Imaging Centre 
located at the Tygerberg Campus of the University of Stellenbosch on a second visit 
before the subjects started cART.  Participants were initially assessed between January 
2008 and December 2009.  Re-assessments were done at 6 months to 1 year after 
commencement of cART to determine whether there were any changes in cognitive 
function from baseline.  At these follow-up visits anthropometry, the clinical assessment 
and neuropsychological test battery was repeated, but blood for follow-up serum samples 
was not collected.  
 
For the present study, I utilized the data and serum that were collected and recorded at 
the baseline and follow-up visits that formed part of the original project.  Data collected for 
the cross-sectional part of my study included socio-demographic information, cognitive 
data (GDS), apolipoprotein E genotype and baseline CD4 count.  HIV infection is 
commonly accompanied by syphilis co-infection (Lynn and Lightman 2004).  A syphilis test 
was, however, not performed at the baseline visit.  The results of serological tests for 
syphilis that were performed around the time of study recruitment, were obtained from the 
clinic records and from the National Health Laboratory Service (NHLS) database for 90 of 
the 114 participants in my study.  Three of these tested weakly positive and 1 positive, but 
there was sufficient time before enrolment into the original study for participants to have 
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completed treatment for the positive syphilis serology.  Data for the longitudinal part of my 
study included the time between baseline and follow-up assessments, duration on cART, 
follow-up GDS and CD4 counts at follow-up (not available for all participants).  All serum 
samples stored at -80°C were thawed on ice and then aliquotted into specimen tubes 
(100µL per tube).  The prepared samples were transported on ice to the CPGR laboratory 
for storage in their freezer at -20°C until the time of analysis.  
 
4.1.7 Data management and analysis 
 
All data, including the results of the cytokine assays, were recorded on a Microsoft Excel 
spread sheet.  Data were prepared for analysis and then imported into the IBM® Statistical 
Package for the Social Sciences (SPSS) version 21 software package for statistical 
analysis.  The level of statistical significance was set at α = 0.05.  Distributions of the 
variables were determined and non-parametric methods were used as appropriate.  The 
specific analyses performed will be discussed in more detail in the results section. 
 
4.1.8 Ethical considerations 
 
This study formed part of a collaborative project between the Departments of Medicine 
(Division of Neurology) and Psychiatry at UCT.  Ethical approval for the study, including an 
amendment for the cytokine assays (19 May 2008), was obtained from the University of 
Cape Town/Groote Schuur Hospital Human Research Ethics Committee (HREC) (No. 
REC 263/2007).  The study adhered to the principles of the 2008 revised International 
Helsinki Declaration (World Medical Association 2009), the South African Guidelines for 
Good Clinical Practice and the Medical Research Council Ethical Guidelines for Research. 
 
4.1.9 Summary of methods 
 
























Figure 4.5 Summary of methods relating to original study 
Participants recruited and screened 
March 2007 - August 2009 
Inclusion criteria: 
• Young adults (18-
35yrs) 
• HIV-positive 
• cART naïve 
• ≥ Grade 7 education 
 
Exclusion criteria: 
• Uncontrolled medical condition 
• Other identified CNS condition 
• Psychotic/mood disorder 
• Recent substance abuse 
• Head injury (LOC>30min) 
Participants enrolled into the study (n=167) 
Baseline assessment 
Informed consent 
Collection of demographic data 
General and neurological exam 
Collection of blood samples 
Routine lab tests (incl.CD4), 
APOE genotyping, serum stored 
@ -80°C 
Cognitive/Neuropsychological test battery 
 
HAND classification 
Global deficit score 
 
One year follow-up 
March 2008-Sep 2010 
(n=109) 
Follow-up assessment 
22 known not on cART 
Cognitive/Neuropsychological test battery  
Collection of blood samples (CD4) 
HAND classification 
Global deficit score 
































Cross-sectional analysis  
Cytokine assays on stored serum: simultaneous 
multianalyte detection (Luminex®) @ CPGR 
Relate APOE ε4, inflammation (cytokine levels) 
and cognition (baseline GDS)
Longitudinal analysis  
Compare GDS at follow-up with GDS at 
baseline to assess cART effect on cognition 
Correlate baseline inflammatory profile with 
change in GDS (cART treatment effect) 
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CHAPTER 5: RESULTS OF THE STUDY 
 
This chapter will begin with a description of the demographic characteristics of the 
participants both in the cross-sectional and the longitudinal components of the study.  The 
CD4, APOE and cognitive data will also be described in this section.  Statistical analyses 
were conducted using SPSS® version 21.  Frequency tables and bar charts were used to 
display categorical demographic data (gender, home language, years of education) while 
summary statistics and histograms were used to display continuous variables (age at first 
assessment, baseline CD4 count, baseline GDS, inflammatory markers).  Normality of the 
data was assessed by means of the Shapiro-Wilk test of normality.  It was determined that 
all variables were skewed in their distribution (SW, p < 0.05).  The appropriate non-
parametric methods were then used to analyse the data.  The results of specific 
hypothesis testing will be presented in the next section.  The chapter will conclude with a 
summary in general terms of the results obtained. 
 
This study aimed to define the role of systemic inflammation in the pathogenesis of HAND 
as well as to determine why some people with HIV develop neurocognitive impairment 
while others do not.  The study will provide information about risk or associative factors 
present at baseline that might predict cognitive response to ART, and identify patients at 
















































Figure 5.1 Flow diagram of participant enrolment and attrition 
Original study (n =167) 
Enrolled (n =114) 
Excluded: 
• No CD4 data (n = 8) 
• No serum (n = 15) 
• Unclear if cART naïve (n 
= 9) 
• Randomly excluded 
(budget restraints) = 12 
Follow-up (n = 40) 
Excluded: 
• Incomplete follow-up data 
(n = 6) 
• No cART (n = 12) 
• cART < 9 months (n = 16) 
Follow-up participants (n = 74) 
Loss to follow-up (n = 40) 
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5.1 Participant characteristics 
 
5.1.1 Cross-sectional component (n = 114) 
 
A total of 114 HIV-positive, cART-naïve participants were evaluated.  The majority of the 
sample were women (n = 91, 80%) and isiXhosa speaking (n = 101, 88.6%).  The median 
age at first assessment was 30 years (IQR = 27-32.5) and the median number of years of 
school education was 10 (IQR = 9-11.25).  The group had a median baseline CD4 count of 
177 cells/µL and a median baseline GDS of 0.5 (mild to moderate cognitive impairment).  
55 participants (48.2%) were carriers of the ε4 allele of APOE (See Table 5-1). 
 
Median age at first assessment (IQR) 
(years) 
30 (27-32.5) 
Gender, n (%) Female 91 (80%) 
Male 23 (20%)  
Median years of education (IQR) (years) 10 (9-11.25) 
Home Language, n (%) isiXhosa 101 (88.6) 
English 7 (6.1) 
Sotho 3 (2.6) 
Afrikaans 1 (0.9) 
Shona 1 (0.9) 
Shangaan 1 (0.9) 
Median baseline CD4 (IQR) (cells/µL) 177 (119-217.5) 
Median baseline GDS (IQR) 0.5 (0.1-0.8) 
APOE ε4 allele, n (%) Present 55 (48.2%) 
Absent 58 (50.8%) 
n = count, IQR = interquartile range 
 
Table 5-1 Demographic characteristics of the participants 
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In order to analyse the participants in terms of cognitive functional ability, three groups 
were created utilizing the GDS criteria, as described in the methods section (see section 
4.1.5, p 60).  Based on this classification, 32 of 114 individuals (28.1%) had severe 
cognitive impairment while 42 of 114 participants (36.8%) were mild to moderately 
impaired in terms of cognitive function.  40 of 114 individuals (35.1%) had no cognitive 
impairment (see Table 5-2). 
Baseline GDS group No (Frequency %) 
1. Normal (GDS < 0.25) 40 (35.1%) 
2. Mild-moderate impairment (0.25 > GDS < 0.75) 42 (36.8%) 
3. Severe impairment (GDS > 0.75) 32 (28.1%) 
 
Table 5-2 Classification into GDS groups based on cognitive scores 
 
The allelic and genotypic frequencies of the APOE gene in the study sample are tabulated 
in Table 5-3 and Table 5-4.  The ε3 allele was found to be most prevalent (60.6%) and the 
frequency of the ε4 allele in the study sample was 28.8%.  The frequency of the 
homozygous ε4 genotype was 8.8%.  
 





Table 5-3 APOE allelic frequencies (n=113) 








Table 5-4 APOE genotypic frequencies (n = 113) 
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Baseline characteristics of the study sample were compared across the categories of 
baseline cognitive function (GDS groups).  The groups were similar in terms of gender 
distribution, home language and median age at first assessment.  The only statistically 
significant difference was in terms of education.  The cognitively normal group had higher 
median years of education compared to the other two groups.  The severely impaired 
group had a lower median CD4 count at baseline, but this difference was not significant.  
The presence of the ε4 allele of APOE did not differ significantly between the groups.  50% 
of the severely impaired group were carriers of the ε4 allele, but 55% of the cognitively 
normal group were also ε4 carriers.  The comparison of baseline characteristics and the 
statistical results are shown in Table 5-5. 
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 GDS group Statistical value 
 Normal 









Χ2 (df) P 
 n = 40 n = 42 n = 32   























202.25 ± 130.55 184.06 ± 
165.78 
3.443 (2) 0.179 
ε4 allele 
present (%) 
22 (55%) 17 (41.5%) 16 (50%) 1.517 (2) 0.620 
n = count; IQR = interquartile range; Χ2 = Chi-square statistic; df = degrees of freedom between 
groups and within groups; p = p value 
Table 5-5 Comparison of baseline characteristics across cognitive function groups 
 
5.1.2 Longitudinal component (n = 40) 
 
A total of 40 participants returned for a follow-up visit and were evaluated.  The majority of 
the sample was women (n = 31, 78%) and isiXhosa speaking (n = 38, 95%).  The group 
had a median follow-up CD4 count of 368.5 cells/µL (IQR = 274.5-571) and median follow-
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up GDS of 0.1 (cognitively normal).  The median time between the baseline and follow-up 
visits was 12.5 months (IQR = 12-14) and median duration time of ART was 12 months 
(IQR = 10-13).  All participants were therefore on ART for at least 9 months prior to their 
follow-up assessment.  20 (50%) participants of the follow-up sample were carriers of the 
ε4 allele of APOE (see Table 5-6). 
 
Gender, n (%) Female 31 (78%) 
Male 9 (23%)  
Home Language, n (%) isiXhosa 38 (95%) 
English 1 (3%) 
Sotho 1 (3%) 
Median follow-up CD4 (IQR) (cells/µL) 368.5 (274.5-571) 
Median follow-up GDS (IQR) 0.1 (0.00-0.38) 
Median months between visits (IQR) 12.5 (12-14) 
Median duration of cART (IQR) 12 (10-13) 
APOE ε4 allele, n (%) Present 20 (50%) 
Absent 19 (47.5%) 
Not available 1 (2.5%) 
n = count; IQR = interquartile range 
Table 5-6 Demographic characteristics of the follow-up group (n = 40) 
At the one-year follow-up cognitive assessment, and after at least 9 months of ART, 
35.1% of the participants were classified into the cognitively normal GDS group and only 
7.5% were classified into the group with severe impairment (Table 5-7).  Figure 5.2 shows 
the GDS groups at baseline and Figure 5.3 shows the follow-up GDS groups.  The 
distribution of baseline GDS groups for 38 participants that did not return for a follow-up 
visit (attrition group) is displayed in Figure 5.4.  There were 29% in the cognitively normal 




Follow-up GDS group Frequency (%) 
1. Normal (GDS < 0.25) 27 (35.1%) 
2. Mild-moderate impairment (0.25 > GDS < 0.75) 10 (25%) 
3. Severe impairment (GDS > 0.75) 3 (7.5%) 
 
Table 5-7 Classification into GDS groups based on follow-up cognitive score  




Figure 5.2 GDS groups at baseline  Figure 5.3 GDS groups at follow-up 
 
 
Figure 5.4 GDS groups at baseline for the attrition group 
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The change in cognitive function from baseline to follow-up will be discussed in more detail 
in the following section. 
 
The baseline and follow-up CD4 counts are compared in Tables 5-8 and 5-9.  Only 1 
participant did not have an improvement in CD4 count at the follow-up visit.  There was a 
significant improvement in CD4 count from baseline to follow-up after initiation of cART (Z 
= -5.484, p < 0.05). 
 
Follow-up CD4-Baseline CD4 n (Count) 
Follow-up CD4 < Baseline CD4 1 
Follow-up CD4 > Baseline CD4 39 
Total 40 
 
Table 5-8 Comparison of follow-up and baseline CD4 count 
 
Baseline CD4 (cells/µL) Follow-up CD4 (cells/µL) Wilcoxon Signed Ranks 
Median (IQR) Median (IQR) Z = -5.484 
p = 0.000** 174.5 (131.5-208) 368.5 (274.5-571) 
IQR = interquartile range, Z = Wilcoxon Signed Ranks statistic, p = p-value 
 
Table 5-9 Comparison of median follow-up and baseline CD4 counts 
 
5.2 Presentation of results by hypothesis 
 
5.2.1 Hypothesis 1 
Hypothesis one stated that in the initial cross-sectional analysis of cART-naïve 
participants, a predominantly pro-inflammatory cytokine profile in the peripheral blood will 
correlate with more severe cognitive impairment.  The converse should therefore also be 
true, i.e. better cognition will be associated with a predominantly anti-inflammatory 
cytokine profile.  In other words, higher concentrations of pro-inflammatory markers in the 
serum will be observed in the group with greater cognitive impairment than in the groups 
with no or less cognitive impairment.  Conversely, greater concentrations of anti-
inflammatory markers will be observed in the group with less cognitive impairment.   As 
discussed in Section 2.3.1 C (p 13), the markers TNF-α and IL-1β were considered “pro-
inflammatory” and the markers IL-10 and TGF-β “anti-inflammatory”.  This hypothesis was 
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tested by two different methods.  In the first method the variables were used individually in 
the analyses.  The second method involved the creation of an inflammatory profile through 
factor analysis.  The baseline CD4 count was explored across categories of GDS and also 
correlated with the individual cytokines.  CD4 count is a proxy marker for AIDS and could 
therefore be a potential confounding factor in both the cytokine concentration levels and 
the degree of cognitive impairment. 
 
Method 1 
The inflammatory markers were first compared across baseline GDS groups.  The Kruskal 
Wallis Test was used to determine whether or not the median values of these continuous 
valued variables differed across the categories of GDS groups.  The Kruskal Wallis Test is 
used in instances where the continuous valued variables are not normally distributed, and 
there are more than two categories in the grouping variable.  The median concentration of 
TNF-α was the highest in the severely impaired group and the median concentration of 
TGF-β was the highest in the cognitively normal group.  There were, however, no 
significant differences for any of the tested variables (p > 0.05; Table 5-10). 
 
Variable GDS group Kruskal Wallis Test 




Χ2 (df) P-value 
 Median (IQR) Median (IQR) Median (IQR)   
TNF-α  4.5 (4.0-6.0) 4.5 (4.0-5.5) 5.0 (4.0-6.2) 1.1 (2) 0.577 
IL-1β 3.5 (2.8-4.0) 3.4 (2.5-4.0) 3.4 (2.5-4.5) 0.89 (2) 0.641 







1.226 (2) 0.542 
IQR = interquartile range; Χ2 = Chi-square statistic; (df) = degrees of freedom between groups and 
within groups; p = p value 
Table 5-10 Comparison of inflammatory markers across GDS groups 
These results are represented graphically by box and whisker plots (Figures 5.5 to 5.8). 
They show median values, interquartile range (25th to 75th percentile) and minimum and 
maximum values of the continuous variables not considered to be outliers for each 
category.  As is shown in Figures 5.4 to 5.6, there were outliers.  However, removal of 
these outliers did not alter the results and the differences between the median 

















Figure 5.8 Comparison of TGF-β across baseline cognitive function groups 
I also treated the GDS as a continuous variable and looked at correlations between 
baseline GDS and the inflammatory markers (Table 5-11).  A higher global deficit score 
implied worse cognitive impairment.  Correlation is the Spearman Rank correlation. 
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No significant correlations were found between the baseline GDS and any of the 
inflammatory markers.  TNF-α was significantly positively correlated with IL-1β (correlation 
coefficient = 0.538, p < 0.0001), and IL-10 was significantly positively correlated with both 
IL-1β and TNF-α (correlation coefficients of 0.372 and 0.258 respectively, with p < 0.0001 
and p = 0.0006). After removing the outliers 31 and 55 for IL-10 and rerunning the 
analysis, the correlation remained non-significant (correlation coefficient = 0.069 and p-
value = 0.468).   The scatterplots for IL-10 and TGF-β are displayed in Figures 5.9 and 
5.10. 
 
Variable Statistic Baseline 
GDS 









    









   















































** Correlation is significant at the 0.01 level (2-tailed); Sig. = Significance (p-value); n = count 
Table 5-11 Correlation between baseline GDS and inflammatory markers 
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Figure 5.9 Correlation of IL-10 with baseline GDS (outliers removed) 
 
Figure 5.10 Correlation of TGF-β with baseline GDS 





N = count; IQR = interquartile range; χ2  = chi-square statistic; df = degrees of freedom 
Table 5-12 Comparison of baseline CD4 across groups of cognitive impairment 
 
The median baseline CD4 count in GDS group 3, the group with severe cognitive 
impairment, was lower than the CD4 count in the other two groups.  There were, however, 
no significant differences between the three GDS groups in terms of baseline CD4 counts. 
After removing outlier 69, the test remained non-significant (p = 0.099).  Fig 5.11 displays 
the box and whisker plot for the comparison of baseline CD4 count across the groups of 
cognitive impairment after removal of outlier 69.  The groups are therefore similar in terms 
of the baseline CD4 count.  
 
 
Figure 5.11 Comparison of baseline CD4 count across groups of cognitive impairment 
(outlier removed) 






Χ2 (df) P-value 
 n = 40 n = 42 n = 32  







149 (96-197) 3.443 (2) 0.179 
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The baseline CD4 count was also compared with the individual inflammatory markers 
(Table 5-13).  I used a Spearman rank correlation analysis because the variables were 
non-normally distributed. 
 
There was no correlation between the baseline CD4 counts and the concentrations of the 
inflammatory markers.  The correlations highlighted (**) were already discussed above.  
After removing the outliers for IL-10, the test was re-run.  There was still no significant 
correlation between IL-10 and baseline CD4 count (Correlation coefficient = 0.102, p = 
0.284, n = 112).  For TNF-α and IL-1β outlier 55 was removed.  After re-running the test, 
the correlation coefficients were 0.1226 and -0.137 respectively, with p = 0.148 and 0.147.  
Scatter plots were used to graphically represent these results.  See Figures 5.12 and 5.13 
for TGF-β and IL-10 (similar trends were seen for IL-1β and TNF-α.) 
 
Variable Statistic Baseline 
CD4 









    









   















































** Correlation is significant at the 0.01 level (2-tailed) 




Figure 5.12 Correlation of TGF-β with baseline CD4 count 
 
 
Figure 5.13 Correlation of IL-10 with baseline CD4 count (outliers removed) 
 
Method 2 – Creating an inflammatory profile 
An inflammatory profile was created by factor analysis.  Factor analysis is a statistical 
variable reduction procedure to reduce the number of variables and to classify variables.  
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Factor analysis enabled me to determine which cytokines grouped together as well as how 
they grouped together based on their weighting.  The first step in factor analysis is the 
identification of the factors, i.e. how many factors are there?  Principal component analysis 
(PCA) was the method used to extract the factors (see Table 5-14).  The Kaiser criterion 
was used to determine the ideal number of factors to extract by using the eigenvalues, 
which are the amount of variance accounted for by a given factor.  The Kaiser criterion 
only retain factors with eigenvalues > 1, i.e. the factor extracts at least as much variance 
as the equivalent of one original variable.  See Table 5-15 for the results of the initial 
exploratory factor analysis.  Low communalities (< 0.3) indicate that the corresponding 
variables have high levels of uniqueness and are not contributing to any particular factor.  
None of my variables had low communalities (Tulsa 2010; Osborne and Costello 2009; 
Santos and Clegg 1999).   
 
Communalities Initial Extraction 
IL-1β 1 0.997 
TNFα 1 0.996 
IL-10 1 0.596 
TGF-β 1 0.568 
 
Table 5-14 Component extraction by principal component analysis 
 
Total Variance Explained 
Component Initial Eigenvalues 
 Total % of Variance Cumulative % 
1 2.019 50.477 50.477 
2 1.137 28.436 78.913 
3 0.838 20.946 99.859 
4 0.006 0.141 100 
 
Table 5-15 Initial exploratory factor analysis 
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The first two factors with eigenvalues > 1 were extracted and then a rotational strategy 
was applied to obtain a clear pattern of the loadings of these factors, that is, factors that 
are somehow clearly marked by high loadings for some variables and low loadings for 
others (see Table 5-16).   
 
Rotated component matrix Component 
 1 2 
IL-1β 0.997 0.048 
TNFα 0.997 0.045 
IL-10 -0.002 0.772 
TGF-β -0.073 -0.75 
 
Table 5-16 Rotated component matrix 
The values in the table are the factor loadings, which is the correlation between the 
measured cytokine concentrations and the new extracted variables (factors).  The factor 
loadings are used to interpret the factors, in other words, to find a common link between 
factors that load highly (are highly correlated with the factor).  This explains which 
variables are grouping together and what the inherent meaning of this grouping is.  Figure 
5.14 displays how the components (factors) plotted in rotated space.  We can see that the 
“pro-inflammatory” cytokines grouped together as component 1.  This component was 
selected for further analyses and for the calculation of the regression (REGR) factor score 
for each participant.   
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Figure 5.14 Component plot in rotated space 
Component 1: IL-1β and TNFα; Component 2: IL-10 and TGF-β 
 
After removing the outliers for IL-1β, TNF-α and IL-10, the PCA was re-run (analysis 1) 
which resulted in the component matrix in Table 5-17.  IL-10 was then removed from the 
analysis and the PCA (analysis 2) resulted in the component matrix in Table 5-18.  IL-1B 
had the highest loading in analysis 1 and, therefore, carried the most weight while TNF-α 
carried the most in analysis 2.  The REGR factor scores relating to these two analyses can 
thus be considered “pro-inflammatory”. 
 

















Table 5-18 Component matrix for analysis 2 
 
These new continuous variables (REGR factor score for analysis 1 and REGR factor 
score) were non-normally distributed.  There was no significant difference when REGR 
factor scores were compared across categories of GDS (Kruskal Wallis test: p = 0.982 and 
p = 0.952 for factor score analysis 1 and 2 respectively).   Likewise, when there was no 
correlation between the factor scores and GDS (Spearman correlation coefficient 0.014, p 
= 0.882 and Spearman correlation coefficient -0.006, p = 0.947 for factor score analysis 1 
and 2 respectively).  REGR factor score for analysis 1 and analysis 2 were correlated (p < 
0.001).  There was also no correlation between the factor scores and baseline CD4 (p = 
0.235 and p = 0.367 for analysis 1 and analysis 2 respectively). 
 
In summary, there were no correlations between individual cytokine levels and the degree 
of cognitive impairment as measured by the GDS category and individual scores.  
Likewise, the systemic cytokine profiles at baseline were not related to the degree of 
cognitive impairment.  These results were not confounded by participant’s ages or their 
CD4 counts which did not differ significantly across the GDS groups. 
 
5.2.2 Hypothesis 2  
Hypothesis 2 stated that in the initial cross-sectional analysis, carriers of the APOE ε4 
allele would have higher systemic levels of cytokines compared with non-ε4 (ε2, ε3) 
carriers. 
 
The individual cytokines were compared across two groups: ε4 allele absent and ε4 allele 
present (see Table 5-19).  There was a tendency for IL-10 levels to be higher in the ε4 
carrier group compared with the non-ε4 carriers, but this trend did not reach statistical 
significance (p = 0.079).  See Figure 5.15 for the box plot comparing IL-10 by ε4 carrier 
status. 
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Variable ε4 allele Kruskal-Wallis Test 
No Yes Χ2 (df) P-value 
n = 58 n = 55 
Median (IQR) Median (IQR) 
IL-1β 3.2 (2.8-4.0) 3.5 (2.5-4.5) 0.42 (1) 0.517 
TNF-α 4.5 (4.0-5.5) 4.5 (4.0-5.5) 0.234 (1) 0.629 
IL-10 7.3 (5.5-9.3) 8.0 (6.5-10.8) 3.077 (1) 0.079** 
TGF-β 904.5 (635.3-
1277) 
919.8 (628.5-1179) 0.004 (1) 0.951 
n = count; IQR = interquartile range; χ2 = Chi-square statistic; df = degrees of freedom 
Table 5-19 Comparison of inflammatory markers with the presence of the ε4 allele 
 
Kruskal Wallis Test: χ2 = 3.225, df = 1, p = 0.079 
 
 
Figure 5.15 Box plot of IL-10 by ε4 carrier status (outliers 31 and 55 removed)  
The cytokines were also compared across categories of ε4 allele status (absent, 
heterozygous or homozygous) (Table 5-20).  Again, there were no significant differences 
across the three categories as determined by the Kruskal Wallis test.  Systemic TGF-β 
concentrations tended to be lower in the ε4 homozygous group compared with the other 
two groups.  This trend, again, did not reach statistical significance.  The box plot for TGF-
β is displayed below (Figure 5.16). 
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Variable ε4 allele status Kruskal Wallis 
Test 
Absent Heterozygous Homozygous Χ2 (df) P-value 
n = 58 n = 45  n = 10 
Median (IQR) Median (IQR) Median (IQR) 
IL-1β 3.2 (2.8-4.0) 3.5 (2.5-4.5) 2.8 (2.0-4.0) 2.067 (2) 0.356 
TNF-α 4.5 (4.0-5.5) 4.5 (4.0-5.5) 4.8 (4.3-6.0) 0.446 (2) 0.8 







4.878 (2) 0.087 
n = count; IQR = interquartile range; χ2 = Chi-square statistic; df = degrees of freedom 
Table 5-20 Comparison of inflammatory markers across categories of ε4 allele status 
 
Figure 5.16 Box plot of TGF-β by categories of ε4 allele status 
I also compared the cytokines across the categories of ε2 and ε3 allele present or absent 
(see Tables 5-21 and 5-22).  The presence or absence of ε2 did not make any difference 
to the cytokine concentrations.  However, a statistically significant association was found 
in TGF-β levels and the presence of the ε3 allele (χ2 = 4.508, df = 1, p = 0.034).  TGF-β 
concentrations were higher in the ε3 group compared with the non-ε3 group.  See Figure 




Variable ε2 allele Kruskal Wallis Test 
No Yes Χ2 (df) P-value 
n = 23 n = 89 
Median (IQR) Median (IQR) 
IL-1β 3.5 (3.0-4.0) 3.5 (2.5-4.5) 0.750 (1) 0.387 
TNF-α 5.0 (3.8-5.5) 4.5 (4.0-5.5) 0.036 (1) 0.849 
IL-10 8.3 (7.0-11.0) 7.5 (6.0-9.65) 2.936 (1) 0.087 
TGF-β 893.3 (425.3-
1298) 
919.8 (631.9-1240.2) 0.209 (1) 0.647 
n = count; IQR = interquartile range; χ2 = Chi-square statistic; df = degrees of freedom 
Table 5-21 Comparison of inflammatory markers across categories of ε2 allele carrier 
status 
 
Variable Ε3 allele Kruskal Wallis Test 
No Yes Χ2 (df) P-value 
N = 18 N = 94 
Median (IQR) Median (IQR) 
IL-1β 3.5 (2.5-4.2) 3.4 (2.5-4.0) 0.490 (1) 0.825 
TNF-α 5.0 (4.0-5.63) 4.5 (4.0-5.5) 0.632 (1) 0.427 





4.508 (1) 0.034 
n = count; IQR = interquartile range; χ2 = Chi-square statistic; df = degrees of freedom 




Figure 5.17 Comparison of TGF-β across categories of ε3 allele present or absent 
The comparison of the REGR factor scores across categories of ε4 carrier status did not 
reveal any significant differences (Chi-square test: p = 0.18 and p = 0.575 for analysis 1 
and 2 respectively).  Likewise, the comparison of the REGR factor scores across 
categories of ε4 allele status was not significantly different (Kruskal Wallis test: p = 0.252 
and p = 0.307 for analysis 1 and 2 respectively). 
 
In summary, there was a tendency for IL-10, an anti-inflammatory cytokine, to be higher in 
ε4 carriers.  However, this did not quite reach statistical significance.  There was also a 
tendency for the concentrations of TGF-β, another anti-inflammatory cytokine, to be lower 
in the ε4 homozygous group compared with ε4 heterozygous and non-ε4 carriers.  TGF-β 
concentrations were significantly higher in ε3 carriers compared with non-ε3 carriers. 
 
5.2.3 Hypothesis 3 
Hypothesis 3 stated that in the cross-sectional analysis, ε4 carriers would have greater 
cognitive impairment (i.e. worse cognitive function) than ε4 non-carriers.  To test this 
hypothesis, the presence of the ε4 allele was compared across the categories of cognitive 
functioning.  Cross-tabulation with contingency tables, clustered bar charts and chi-
squared tests of association were used.  There was no significant association between the 
presence of the ε4 allele and the cognitive function group: χ2 = 1.517, df = 2, p = 0.468 
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Statistic ε4 allele present Total 
No Yes 
1 Count (n =) 
% Within baseline GDS group 1 










2 Count (n =) 
% Within baseline GDS group 2 










3 Count (n =) 
% Within baseline GDS group 3 










Total Count (n=) 
% Within baseline GDS group 











Table 5-23 Presence of the ε4 allele across categories of baseline cognitive functioning 
 
Figure 5.18 Presence of the ε4 allele across groups of cognitive functioning 
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The status of the ε4 allele, whether absent (0 ε4 alleles), heterozygous (1 ε4 allele) or 
homozygous (2 ε4 alleles), was also compared across GDS groups of cognitive 
functioning (see Table 5-24).  No significant associations were found: χ2 = 1.523, df = 4, p 
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Table 5-24 Comparison of ε4 allele status across categories of cognitive functioning 
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Figure 5.19 ε4 allele status across groups of cognitive functioning 
The presence of the ε2 and ε3 alleles was also compared across groups of cognitive 
function.  There were no statistically significant results (Chi-square: χ2 = 4.030, df = 2, p = 
0.133 for ε2 and Chi-square: χ2 = 4.731, df = 2, p = 0.94 for ε3). 
In summary, there was no significant association between ε4 carrier status and cognitive 
impairment.  The presence of the ε4 allele was not associated with greater cognitive 
impairment compared with ε2 and ε3 carriers. 
  
5.2.4 Hypothesis 4 
Hypothesis 4 stated that participants with an initial pro-inflammatory cytokine profile at 
baseline would respond better to cART in terms of cognitive function than those with an 
initial anti-inflammatory profile.  A predominantly pro-inflammatory baseline profile would 
be associated with more improvement in cognitive function at follow-up.  Conversely, a 
predominantly anti-inflammatory baseline profile would be associated with less 
improvement in cognitive function at follow-up.   
 
To test this hypothesis, a new variable called “GDS change” was created to reflect the 
change in the global deficit score over time.  This variable had three categories describing 
the status of cognitive function: maintained, worsened, and improved.  In the sample of 
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patients who returned for follow-up, 60% had improved cognitive function after at least 9 
months of cART.  17,5% worsened and 22.5% maintained their level of cognitive 
functioning when re-tested at their follow-up visit (see Table 5-25). 
 




Maintained 9 22.5 22.5 22.5 
Worsened 7 17.5 17.5 40 
Improved 24 60 60 100 
Total 40 100 100  
 
Table 5-25 Change in GDS over time 
A second variable called “GDS change 2” was then created to describe the treatment 
effect over time.  This variable has two categories: positive treatment effect and negative 
treatment effect.  The positive treatment effect category included all participants who 
improved or maintained their cognitive function at follow-up after initiating cART.  The 
negative treatment effect category included all participants whose cognitive function 
worsened.  From Table 5-26 we can see that there was a positive treatment effect in 
82.5% of the follow-up sample.  
 




Positive treatment effect 33 82.5 82.5 82.5 
Negative treatment 
effect 
7 17.5 17.5 100 
Total 40 100 100  
 
Table 5-26 ART effect on cognitive function over time 
A comparison was then made between the baseline and follow-up GDS groups by means 
of cross-tabulation and the McNemar test: χ2 = 10.07, df = 3, p = 0.018.  There was a 
significant correlation between the change in GDS group over time and the baseline GDS 
group (see Table 5-27).   Individuals in baseline group 1 were more likely to be in follow-up 
group 1 (normal) than those in groups 2 (mild-moderately impaired) and 3 (severely 
impaired). Similarly, individuals originally in group 2 were more likely to be in follow-up 
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group 1 than those originally in group 3.  Those in groups 2 and 3 were more likely to be in 
follow-up groups 2 or 3 than group 1.  (Also refer to the clustered bar chart in Figure 5.20.)  
 
In other words: Individuals who had normal cognitive function at baseline were more likely 
to maintain their cognitive function (remain normal) at follow-up than those who were 
impaired at baseline.  It was more likely that an individual with mild to moderate cognitive 
impairment (group 2) at baseline would improve to normal at follow-up than it was for an 
individual with severe cognitive impairment (group 3) at baseline.  It was also more likely 
that individuals with mild to moderate (group 2) or severe cognitive impairment (group 3) at 
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Table 5-27 Comparison of baseline and follow-up GDS groups 
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Figure 5.20 Comparison of baseline and follow-up GDS groups 
The next step was to compare the inflammatory profile, described in Hypothesis 1, to the 
change in GDS.  For this analysis, GDS change was treated as a continuous variable and 
the Spearman rank correlation was used.  The inflammatory profile at baseline was not 




Variable Statistic GDS 2 – GDS 1 REGR factor 
score 1 for 
analysis 1 
REGR factor 
score 1 for 
analysis 2 













































Table 5-28 Comparison of baseline inflammatory profile to GDS change 
 
 
Figure 5.21 Comparison of baseline inflammatory profile to GDS change 
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Figure 5.22 Comparison of baseline inflammatory profile to GDS change 
The GDS change was also treated as a categorical variable with the three categories: 
maintained, worsened, and improved.  The continuous inflammatory variables (factor 
scores for analyses 1 and 2) were then examined by categories of GDS change.  There 
were no significant differences between the two continuous inflammatory variables in 
terms of the change in GDS group (see Table 5-29 and Figures 5.23 and 5.24). 
 
Variable GDS change 
group 
Median (IQR) Kruskal Wallis Test 
p-value 
REGR factor 
score 1 for 
analysis 1 
Maintained  0.03 (-0.47-0.53) 
0.566 Worsened -0.09 (-0.67-0.06) 
Improved -0.52 (-0.52-0.27) 
REGR factor 
score 1 for 
analysis 2 
Maintained -0.12 (-0.45-0.45) 
0.719 Worsened -0.29 (-0.72-0.14) 
Improved -0.49 (-0.49-0.43) 
 








Figure 5.24 Comparison of baseline inflammatory profile by groups of GDS change 
The continuous inflammatory variables were also examined across the categories of GDS 
change (positive or negative treatment effect).  The Mann-Whitney test (non-parametric t-
test) was used, and again there were no significant differences across the groups.  (See 
Table 5-30 and Figures 5.25 and 5.26.) 
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Variable GDS change group Median (IQR) Mann-
Whitney Test 
p-value 
REGR factor score 
1 for analysis 1 
Positive treatment effect -0.03 (-0.51-0.35) 
0.788 Negative treatment 
effect 
-0.09 (-0.67-0.06) 
REGR factor score 
1 for analysis 2 
Positive treatment effect -0.23 (-0.48-0.38) 




Table 5-30 Comparison of baseline inflammatory profile across treatment effect groups 
 
 
Figure 5.25 Comparison of baseline inflammatory profile across treatment effect groups 
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Figure 5.26 Comparison of baseline inflammatory profile across treatment effect groups 
The individual baseline cytokine concentrations were also compared to the change in 
GDS.  There were no statistically significant correlations or associations between baseline 
cytokine concentration and change in GDS at follow-up.  Figure 5.27 displays the scatter 
plot for the correlation of TGF-β with change in GDS (Spearman’s correlation coefficient = 
0.272, p = 0.09).  (Similar trends were seen for IL-1β, TNF-α, and IL-10.) 
 
Figure 5.27 Correlation of TGF-β with change in GDS 
In summary, there was no significant correlation or association between the individual 
cytokine levels or systemic cytokine profile and the cognitive response to cART. 
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5.3 Summary of results 
 
5.3.1 Baseline participant characteristics 
 
• 114 participants were studied at baseline. 
• Participants were primarily female and isiXhosa-speaking. 
• The median age (IQR) was 30 (27-32.5) years. 
• At baseline, 40 participants had no cognitive impairment (GDS group 1), 42 had 
mild-moderate cognitive impairment (GDS group 2), and 32 were severely impaired 
(GDS group 3). 
• The median CD4 count (IQR) was 177 (119-217.5) cells/µL and did not differ 
significantly amongst the 3 GDS groups. 
• The median number of years of education for all participants (IQR) was 10 (9-
11.25), but participants in GDS group 1 had significantly higher years of education 
compared with the other 2 groups. 
• The ε4 allelic frequency in the study population was 0.29.  
• The proportion of ε4 carriers did not differ significantly amongst the 3 GDS groups.  
 
5.3.2 Follow-up participant characteristics 
 
• Of the original baseline participants, 40 were studied at least 9 months after ART. 
• The distribution of participants in the GDS groups at the follow-up assessment 
differed from the distribution at baseline.  There were fewer severely impaired 
participants in the follow-up group. 
• However, the attrition group had a larger proportion of participants with severe 
cognitive impairment than the group who returned for follow-up had at baseline. 
• Median CD4 counts were significantly higher at the follow-up visit. 
 
5.3.3 Results by hypothesis 
 
Hypothesis 1 
• There was no correlation between individual cytokine levels and the degree of 
cognitive impairment as measured by the GDS category and individual scores.  
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Likewise, the systemic cytokine profiles at baseline were not related to the degree 
of cognitive impairment.   
• These results were not confounded by participant’s ages or their CD4 counts which 
did not differ significantly across the GDS groups.  There were no correlations 
between the baseline CD4 count and cytokine levels. 
 
Hypothesis 2 
• There was a tendency for IL-10, an anti-inflammatory cytokine, to be higher in ε4 
carriers.  However, this did not quite reach statistical significance.   
• There was also a tendency for the concentrations of TGF-β, another anti-
inflammatory cytokine, to be lower in the ε4 homozygous group compared with ε4 
heterozygous and non-ε4 carriers. 




• There was no significant association between ε4 carrier status and cognitive 
impairment.  The presence of the ε4 allele was not associated with greater cognitive 
impairment compared with ε2 and ε3 carriers. 
 
Hypothesis 4 
• There was no significant correlation or association between the individual cytokine 











CHAPTER 6: DISCUSSION 
 
6.1 Summary of rationale for the study 
 
HIV-1 is a major global health concern and South Africa has the highest number of 
PLWHA in the world (WHO and UNICEF 2011).  The HIV-associated neurocognitive 
disorders affect around 50% of HIV-infected people and can range in severity from mild 
deficits to a debilitating dementia (Heaton et al. 2010; Ellis et al. 2009; McArthur et al. 
1993b).  High prevalence rates for HIV-associated dementia (25.3%) and mild 
neurocognitive disorders (42.2%) have been reported in Cape Town, South Africa.  The 
pathogenesis of HAND is still unclear, but neuroinflammation is believed to play a key role.  
There is also increasing evidence that repeated acute infections or chronic systemic 
infections, through signalling from the periphery to the CNS, may enhance the 
neuroinflammation that ultimately leads to neurodegeneration.  Most of our understanding 
of the disease progression of HIV-1 is, however, based on research findings from 
countries where subtype (clade) B HIV-infection predominates.  These findings may not be 
generalizable to populations in sub-Saharan Africa where HIV-1 clade C infection is most 
common (Ellis et al. 2009; Kanki et al. 1999).  There are still limited data available about 
the neurological complications of HIV-1 clade C.  The ε4 allele of APOE has been 
investigated as a risk factor for the development of HAND.  African populations have a 
higher frequency of the ε4 allele and in South Africa this allele was found to have a high 
prevalence among isiXhosa speakers (Joska et al. 2010a). 
 
A study of the relationships between systemic infection, APOE genotype and cognitive 
impairment is biologically important and clinically relevant in the South African setting 
where clade C HIV-infection predominates. 
 
In this study we aimed to understand more about the role of systemic inflammation in CNS 
neurodegeneration and the pathogenesis of HAND.  From a clinical perspective, we hoped 
to identify risk factors for HIV-associated dementia.  We also hoped to identify factors 
associated with cognitive response to cART.  These factors would then enable us to 
predict which cognitively impaired patients would respond better to cART.  We hoped that 
our findings might help us identify patients at risk of developing HAND who might benefit 
from earlier initiation of cART. 
 
 110 
6.2 Summary of what the study entailed 
 
This retrospective, observational study had 2 components:  The cross-sectional 
component involved 114 participants who were recruited as part of an existing research 
project.  Participants were young HIV-positive, cART-naïve adults from primary care ARV 
clinics in Cape Town, South Africa.  All participants completed baseline assessments 
where demographic data were collected, a general physical and neurological examination 
was performed and cognitive function was assessed using a neuropsychological test 
battery.  Blood was also collected for routine laboratory tests and APOE genotyping.  
Serum was prepared and pro-and anti-inflammatory cytokines were measured in the 
stored samples.  Global deficit scores were calculated from the cognitive tests.  These 
scores were correlated with the cytokines and with APOE data.  The longitudinal data of 
40 participants who returned for follow-up assessments after at least 9 months on cART 
were analysed.  The GDS at follow-up were compared with GDS at baseline to determine 
cognitive responses to cART.  Correlations were made between baseline cytokine profiles 
and cognitive responses. 
 
We hypothesised that a predominantly pro-inflammatory cytokine profile in the peripheral 
blood of HIV-positive participants not yet on cART would correlate with greater cognitive 
impairment.  Conversely, better cognition would be associated with a predominantly anti-
inflammatory cytokine profile.  Participants with an initial pro-inflammatory cytokine profile 
would also respond better to cART in terms of cognitive function.  We also hypothesised 
that the presence of the ε4 allele of APOE would be associated with more inflammation 
and also with greater cognitive impairment. 
 
Next, I shall discuss the results of this study by first looking at the participant 
characteristics and then at the results per hypothesis.  Following this I shall discuss the 
limitations of this study and recommendations for future research. 
 
6.3 Participant characteristics 
 
90% of the study population was isiXhosa speaking.  In South Africa, isiXhosa is the 
second largest language and is the first language of 24.7% of people in the Western Cape.  
Cape Town has the second largest population of major cities in South Africa and 38.6% of 
the population are “black African” (Census 2011).  Of the South African population, almost 
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80% are indigenous African. The demographic profile of my sample was thus 
representative of that of the South African population. 
 
Participants in the study were mainly female.  This is not surprising because it is estimated 
that 51% of the South African population are female and roughly 17% of women in their 
reproductive years are HIV-positive.  In South Africa the majority of HIV-infected people 
who attend clinics are female and may present with late-stage disease (Joska et al. 2011).  
Women tend to seek medical attention more readily than men (Cleary et al. 1982).  The 
Global AIDS report (2010) indicated that slightly more than half of all PLWHA were female 
and in sub-Saharan Africa; more women were living with HIV than men (WHO and 
UNICEF 2011).   
 
The median age of study participants was 30 years.  The study specified an age inclusion 
criterion of 18 to 35 years, partly to exclude the confounding effects of neurodegenerative 
diseases associated with older age.  Advancing age has been associated with the 
development of HAND.  Valcour et al found a significantly higher frequency of HAD in the 
older (50 or more years old) compared to the younger (20-39 years old) groups of the 
Hawaii Aging with HIV Cohort (Valcour et al. 2004b).  Neuropathological similarities also 
exist between Alzheimer’s disease and HAND.  A study by Esiri et al found that the 
prevalence of Alzheimer plaque formation increased with age in healthy older controls.  
However, the brains of patients with AIDS showed an increased propensity to Alzheimer 
plaque formation at a younger age (in their fourth decade) compared with the controls.  
They proposed that the trigger for plaque formation is the neuroinflammatory response 
associated with AIDS (Esiri et al. 1998).  There was no significant age difference between 
the baseline GDS groups in my study sample and age was therefore not considered to be 
a confounding factor in the analyses involving cognitive impairment.   
 
A lower level of education may be linked to high-risk behaviour due to less health 
awareness and less sex education.  The lack of adequate sex education and resulting 
high-risk behaviour can increase the likelihood of people being infected with HIV.  In South 
Africa, people with an education level of less than 10 years of schooling are largely 
employed in manual labour jobs.  The availability of jobs in the manual labour market is 
scarce, leading to a high unemployment rate in this group of people.  Unemployment leads 
to poor socio-economic conditions, which in turn, are associated with higher risk 
behaviour.  Lower levels of education have been associated with poor cognitive reserve in 
 112 
Alzheimer’s disease studies and also play a role in age-related cognitive decline (Stern 
2006; Scarmeas and Stern 2003).  Likewise, HAND has been associated with lower levels 
of education.  In my study, the median level of education for the group was 10 years with 
an IQR of 9 to 11.25.  Participants in baseline GDS group 1, the group with no cognitive 
impairment, had significantly more years of education compared with the other two groups.  
Findings from the Multicenter AIDS Cohort Study in the US suggested that low education 
(< 12 years) might be a risk factor that lowers the threshold for neuropsychological 
abnormalities in HIV-1 infection (Satz et al. 1993).  Joska et al also found a significant 
inverse relationship between level of education and level of cognitive impairment in a large 
cohort of HIV-1-infected patients in South Africa (Joska et al. 2010b).  These findings are 
similar to results from other studies in sub-Saharan Africa where lower education levels 
were associated with lower neuropsychological performances (Kanmogne et al. 2010; 
Lawler et al. 2010).  It is also possible that lower levels of education could have affected 
performance in the cognitive tests.  In other words, those with less education performed 
more poorly on cognitive tests, resulting in them being diagnosed as “more impaired”.  On 
the other hand, a selection bias has been introduced into the study by excluding people 
with less than 7 years of education.  In doing so we may have excluded a large number of 
HIV-infected individuals with severe cognitive impairment. 
 
The ε3 allele was found to be most prevalent (60.6%) in my study population and this is in 
keeping with reported data from all populations (Eichner et al. 2002).  The frequency of the 
ε4 allele in the study sample was 0.29, which is high compared with the prevalence of the 
ε4 allele in populations from European descent, but is comparable to the higher 
prevalence of ε4 reported in populations of southern Africa (Eichner et al. 2002; Zekraoui 
et al. 1997; Farrer et al. 1997).  The frequency of the homozygous ε4 genotype (8.8%) in 
this study population is more in keeping with the findings in the Khoi-San (10%) than with 
Europeans (2-3%) (Sandholzer et al. 1995).  The participants in my study were 
predominantly “indigenous African” and it is therefore not unexpected that the prevalence 
of ε4 is comparable to the rates found in other southern African populations.  The 
proportion of ε4 carriers did not differ significantly amongst the three baseline GDS groups 
in my study sample.  Carrying the ε4 allele did therefore not influence the degree of 
cognitive impairment.  I shall discuss more about APOE genotypes in Hypothesis 3. 
 
There was a high prevalence of mild to moderate cognitive impairment at baseline (37%), 
while 28% of the participants had severe cognitive impairment.  These rates are similar to 
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the findings of Joska et al. who reported the prevalence of MND and HAD in South Africa 
as 42.4 and 25.4% respectively (Joska et al. 2010d).  High rates for HIV-associated 
dementia have also been reported in studies in Uganda (31%) and India (35%) (Wong et 
al. 2007; Riedel et al. 2006).  However, a much lower prevalence rate of HIV-dementia 
(only 2%) was reported by the CNS HIV Antiretroviral Therapy Effects Research 
(CHARTER) study in America.  They also found lower rates of MND than those in sub-
Saharan Africa (Heaton et al. 2010).   
 
Why are higher rates of moderate to severe cognitive impairment reported in South Africa 
and other developing countries?  The lower socio-economic status and poorer health care 
in third world countries may make people more vulnerable to developing cognitive 
impairment.  Poor nutrition has been associated with the development of cognitive 
impairment, while in South Africa access to cART is still incomplete and people present 
with late stage HIV-disease (Joska et al. 2010d; Robertson et al. 2007; González-Gross et 
al. 2001; Guenter et al. 1993).  We might be seeing the effect of a more neurovirulent and 
neurotoxic subtype of HIV-1.  The HIV epidemic in South Africa and sub-Saharan Africa is 
largely due to clade C of HIV-1.  Although there are varying reports about the neurotoxicity 
of clade C versus clade B virus, it remains undetermined whether clade C is more likely to 
cause cognitive impairment.   
 
Could it be that we are overestimating the problem of HAND?  PLWHA, especially those 
who present with more advanced disease, may have other undetected systemic infections 
which could confound the results of cognitive testing.  Many of the cognitive tests have not 
been fully validated in our population.  However, z-scores were calculated from the HIV-
negative control data and then used to determine each participant’s degree of impairment 
relative to the means of the control sample.  The participants in the control group were 
age-matched and recruited from the same clinics as the study sample.  As previously 
discussed, it is also possible that those with less education scored lower in the cognitive 
tests because they were less skilled in the tasks required by the tests and not because 
they had worse cognitive impairment.  Better-validated education-adjusted cognitive tests 
may need to be developed before further investigating the neuro-cognitive effects of HIV-1 
clade C in developing countries.  So doing, we would also be able to include HIV-infected 
individuals with less than 7 years of education. 
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The median CD4 count of participants at baseline assessment was 177 cells/µL.  The 
median baseline CD4 count in GDS group 3, the group with severe cognitive impairment, 
was lower than the CD4 count in the other two groups, although this was not statistically 
significant.  A low nadir CD4 count has been shown to contribute to the development of 
HAND (Heaton et al. 2010; Childs et al. 1999).  The lower CD4 count in the HIV-dementia 
(GDS 3) group was not an unexpected finding since patients with HIV-associated 
dementia tend to have more advanced HIV infection with lower CD4 counts.  Joska et al 
also found a tendency towards lower CD4 counts in patients with HIV-dementia (Joska et 
al. 2010d).  The baseline CD4 counts for this study were collected from patients’ clinic 
records and were assumed to be the nadir count, because all participants were about to 
enter an ART programme.  However, the waiting time to initiation of ART may have varied 
amongst the participants.  In many the CD4 count could have declined further so the true 
nadir count might have been even lower.  The median CD4 counts were significantly 
higher at the follow-up visit.  Increased CD4 count and restored immune function due to 
cART may benefit the CNS by reducing the number of circulating, activated monocytes, as 
well as their migration into the brain.  The BBB may be less permeable to the influx of 
inflammatory cells from the systemic circulation when systemic inflammation levels are 
reduced.  This would in turn lead to lower levels of immune activation and 
neuroinflammation, which would be beneficial to cognitive function (Liner II et al. 2008; 
Sinclair et al. 2008; McArthur et al. 2004). 
 
At the one-year follow-up cognitive assessment, and after a median of 12 months on 
cART, there were significantly fewer participants with severe cognitive impairment than at 
baseline (7.5% compared to 28%).  Neurological improvement due to cART remains 
variable, but the majority of individuals improve after up to a year on treatment (Cross et 
al. 2013; Joska et al. 2010c).  It is possible that the follow-up GDS groups could include 
potential selection bias.  The very sick or impaired patients did not return for the follow-up 
visit because they passed away or were too cognitively impaired.  In fact, of 38 











There was no association between the individual cytokine concentrations or the cytokine 
profile measured in the peripheral blood and the degree of cognitive impairment. 
 
The cytokines I selected for analyses are those that have been most studied in the context 
of HIV-associated cognitive impairment (Matsumura et al. 2008; Brabers and Nottet 2006; 
Zhao et al. 2001; Tyor et al. 1992).  These cytokines were, however, often measured in 
brain tissue or in the CSF of patients with known cognitive impairment.  Some studies 
have demonstrated an association between elevated cytokine levels in the CSF and HIV-
associated cognitive impairment (Yuan et al. 2013; Wesselingh et al. 1993).  The CSF 
compartment, however, may not shed much light on the pathogenesis of HIV in the brain.  
The blood compartment may be more informative and is also more readily accessible 
(McGuire 2009).  The peripheral and central cytokine compartments appear to be 
integrated: cytokines can cross the BBB, and components of the peripheral immune 
system can therefore initiate an inflammatory process in the brain (Allan and Rothwell 
2003; Szelenyi 2001).  Few researchers have, however, attempted to correlate cytokines 
in the peripheral blood and cognitive impairment.  A study by Ryan and colleagues failed 
to show a significant association between the levels of TNF-α in the blood and cognitive 
impairment in HIV-infected patients.  The small numbers of participants in the study by 
Ryan had late stage HIV-disease and were on cART (Ryan et al. 2001).  The ART could 
have lowered the levels of TNF-α in the blood and the numbers might have been too small 
to detect significant differences between HIV-infected patients with and without cognitive 
impairment.  A smaller study by our group did show significant correlations between 
systemic cytokines and the degree of cognitive impairment in HAD.  Patients with severe 
cognitive impairment had higher levels of IL-1β, as measured by ELISA, compared with 
participants who were mildly impaired or cognitively normal (Mahne 2010).  The lack of 
correlations between the cytokines and the degree of cognitive impairment in my study 
was disappointing.  It is possible that the multi-analyte detection technique did not 
accurately measure the concentrations of cytokines in the serum.  Only a small number of 
samples elicited a response above that of the control level for IL-1β, TNF-α, and IL-10.  
Cytokine concentrations may have been too low and therefore not an accurate reflection of 
the inflammatory status at baseline.  The manner in which the samples were processed 
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and stored could also have affected the results.  Of course, it is possible that the blood 
was just not the best compartment for measuring inflammatory components that impact on 
inflammation in the brain.  This is, however, contrary to the findings of numerous studies 
that “link” systemic inflammation and neuroinflammation. 
 
“Pro-inflammatory” cytokines can be neurotoxic, while “anti-inflammatory” cytokines can be 
neuroprotective.  In the correlation of the cytokines with baseline GDS, the “pro-
inflammatory” cytokines IL-1β and TNF-α were significantly positively correlated with each 
other.  This is to be expected because they are both “pro-inflammatory” markers.  IL-10, 
an “anti-inflammatory” cytokine was also positively correlated with IL-1β and TNF-α.  This 
might have been because IL-10 increased in response to the increase in IL-1β and TNF-α 
in an attempt to suppress or dampen the inflammatory processes.  IL-10, a normally anti-
inflammatory cytokine, could also have been functioning in a “pro-inflammatory” state.  
Thus, the functions of cytokines overlap significantly.  The role of a specific cytokine can 
also change over time.  I thought that the creation of an inflammatory profile might 
therefore more accurately represent the inflammatory state at any given time.  The 
breakdown in the balance between pro- and anti-inflammatory cytokines in the brain might, 
after all, lead to neurodegeneration (González-Scarano and Martin-Garcia 2005).  The 
inflammatory profile I attempted demonstrated how the cytokines group together; I could 
conclude that IL-1β and TNF-α functioned in a similar manner, presumably as pro-
inflammatory cytokines.  I did not, however, find any correlation between the inflammatory 
profile and the degree of cognitive impairment.  More sophisticated statistical models may 
be required to relate multiple cytokine measurements to cognitive function  
 
The CD4 count is a measure of the severity of HIV-disease and therefore probably serves 
as a proxy marker of disease duration in cART-naïve patients.  It could be argued that 
disease severity might have been a confounding factor in my analyses.  For example, the 
failure to demonstrate an association between cytokine levels and cognition might have 
been due to the fact that I had a heterogeneous group of patients with varying degrees of 
disease severity.  If numbers were greater, I might have been able to examine the 
association between cytokines and cognition in smaller groups subdivided according to 
their CD4 ranges.  It could be that the cytokine associations with cognition depended on 
HIV-disease severity (AIDS staging).  There was, however, no correlation between 
baseline CD4 counts and the cytokine levels or the degree of cognitive impairment.  
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Median CD4 counts, in fact, did not differ between the three GDS groups.  Disease 




The presence of the ε4 allele of the APOE gene was not associated with increased levels 
of pro-inflammatory cytokines in the peripheral blood. 
 
The ε4 allele of APOE has been associated with increased levels of pro-inflammatory 
cytokines in the peripheral blood and CNS of transgenic mice in vivo (Lynch et al. 2003; 
Harry et al. 2000).  ApoE4 has also been found to be less effective at down-regulating the 
brain’s inflammatory response than apoE3 (Lynch et al. 2003; Harry et al. 2000).  There 
was a tendency of IL-10 to be higher in ε4 carriers, but this was not statistically significant.  
IL-10 is a predominantly anti-inflammatory cytokine and this finding would appear to 
contradict what the research has shown.  The ε4 allele has been associated with a trend 
toward lower IL-10 serum levels in a study of patients with coronary artery disease 
(Tziakas et al. 2006).  However, IL-10 might have been raised in an attempt to suppress 
the inflammation initiated by the pro-inflammatory cytokines.  It is also possible that the 
inflammatory processes in general, both pro- and anti-inflammatory, are higher in the 
presence of the ε4 allele.  It has been hypothesised that ε4 allele carriers may show an 
inflammatory imbalance between pro- and anti-inflammatory cytokines.  The role of apoE 
has been well described in the neuroinflammatory pathogenesis of AD where apoE has 
both anti- and pro-inflammatory CNS effects.  Could it be possible that apoE play a more 
anti-inflammatory role in the brain with apoE4 being a less effective anti-inflammatory 
isoform than E2 or E3?  Guo and colleagues also examined the effects of apoE3 and 
apoE4 on IL-1β in the absence of amyloid-β in vitro.  Both apoE3 and apoE4 stimulated IL-
1β production in a dose-dependent manner.  However, apoE4 displayed significantly more 
robust pro-inflammatory activity (Guo et al. 2004).  In my study, the concentrations of TGF-
β tended to be lower in the ε4 homozygous group compared with the ε4 heterozygous 
group and non-ε4 carriers.  This finding was not statistically significant, but it would have 
supported the hypothesis that carriers of the ε4 allele tend to have lower levels of anti-
inflammatory cytokines, and are thus more vulnerable to the neurotoxic effects of the pro-
inflammatory cytokines, as described in the literature.  This susceptibility may be more 
pronounced in the presence of two ε4 alleles.  TGF-β concentrations in this study were 
significantly higher in ε3 carriers compared with non-ε3 carriers.  ApoE3 has been shown 
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to be neuroprotective (Hayashi et al. 2007; Sabo et al. 2000; Pedersen et al. 2000).  
Carriers of the APOE ε3 allele have also been shown to be more effective at down-
regulating neuroinflammation.  Furthermore, it has been reported that lipoproteins 
containing the apoE3 isoform have higher levels of TGF-β than those containing apoE4.  
The predominantly anti-inflammatory and neuroprotective properties of TGF-β might 




The presence of the ε4 allele of the APOE gene was not associated with worse cognitive 
function. 
APOE ε4 has been identified as a risk factor for AD.  It has also been investigated as a 
host risk factor for the development of HIV-associated cognitive impairment.   There was 
no significant association between ε4 carrier status and cognitive impairment in this study.  
Studies investigating the relation between ε4 and HAD have produced conflicting results.  
Those with positive findings were either studies in non-Clade C countries or the 
relationship was dependent on advanced age (Valcour et al. 2004a; Corder et al. 1998). 
Several studies have failed to demonstrated a relationship between APOE ε4 and HAD.  
The study by Joska and colleagues was the first in South Africa to evaluate this 
relationship.  They did not find any differences in the allelic frequencies of APOE across 
the categories of HAND (Joska et al. 2010a).  Unlike the finding of a significantly lower ε4 
allelic frequency in patients with HAD noted in the study by Joska, the percentage of ε4 
carriers in the severely impaired group in my study was not significantly different 
compared with the other two groups.  In fact, 50% of the participants in GDS group 3 were 
carriers of the ε4 allele compared with 55% in the cognitively normal group.  The latter 
does show the high ε4 allelic frequency of HIV-infected patients.  Burt et al. reported that 
apoE4 predisposes cells to a significantly higher rate of HIV cell infection in vitro.  Carrying 
two ε4 alleles was associated with an accelerated HIV disease course, compared to the ε3 
allele that was associated with a slower disease course (Burt et al. 2008).  ApoE4 affects 
the dynamics of HIV infectivity and disease progression, and more advanced disease is 
associated with HAND.  The high prevalence of the ε4 allele in my study sample may have 
made them susceptible to acquiring HIV-infection and may also have predisposed them to 
develop more advanced disease and cognitive impairment.  The association between ε4 





A predominantly pro-inflammatory cytokine profile at baseline was not associated with 
greater improvement in cognitive function at follow-up. 
 
More than 50% of the participants who initiated cART and returned for the follow-up 
assessment had improved cognitive function and more than 80% had a positive treatment 
effect i.e. they maintained or improved cognitive function.  There was also a significant 
change in GDS group from the baseline to the follow-up visit.  This improvement in 
cognition due to cART is in keeping with numerous reports demonstrating the beneficial 
effects of cART on preserving or improving cognitive function (Cross et al. 2013).  In this 
study, the participants with normal cognition at baseline did not deteriorate.  It was less 
likely for participants with severe cognitive impairment at baseline to improve to normal at 
follow-up.  A degree of cognitive impairment thus remained in these participants despite 
treatment with cART.  This is in keeping with findings from other studies that 
neuropsychological improvement is not complete.  The improvement in cognitive function 
following cART is variable and some patients still improve after up to a year on cART 
(Joska et al. 2010c).  The median duration of cART before the follow-up visit in this study 
was 12 months.  It is therefore possible that some patients might have improved further 
after the follow-up assessment. 
 
Early improvement in cognitive function due to cART can be due to improved immune 
function and the suppression of systemic, as well as neuroinflammation.  I did not find a 
correlation between the baseline cytokine profile and the degree of cognitive improvement.  
Levels of systemic inflammation at baseline did not predict greater improvement in 
cognitive function due to cART.  The reason for this lack of correlation might have been 
related to technical aspects as discussed in Hypothesis 1.  Although the initial response to 
cART involves suppression of inflammation, it might be that this response is too variable 
and therefore cannot be accurately predicted by measuring cytokine concentrations in the 
peripheral blood before cART initiation.  It would have been useful to have measurements 
of the same cytokine concentrations at the follow-up visit to determine whether a 
difference was present between baseline and follow-up in those patients who improved on 
cART.  There might also be a degree of on-going chronic inflammation in the brain that is 
not suppressed by cART, which might also explain why a degree of cognitive impairment 
persists in some.   
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6.5 Limitations of the study and recommendations for future research 
 
One limitation of my study was its partial retrospective nature.  The initial demographic and 
cognitive data had already been collected prior to my involvement.  Incomplete data 
collection led to the exclusion of a number of participants.  Due to the high laboratory 
costs, I could only use a limited number of cytokines for analysis.  My sample size of 114 
participants for the cross-sectional analysis was, however, probably adequate to give the 
study reasonable power.  This sample size was also similar to other HAND studies in the 
developing world such as Uganda, Cameroon and India (Kanmogne et al. 2010; Wong et 
al. 2007; Yepthomi et al. 2006).  However, the attrition rate was high.  The loss to follow-
up probably related to the poor socio-economic conditions of the study population, 
financial constraints, lack of transport and inability to leave a job and risk losing their pay 
for the day.  It is also possible that some of the participants who had severe impairment in 
cognitive function at baseline were lost to follow-up because they deteriorated further or 
died.  Participants were only included in the longitudinal analysis if they had at least 9 
months of cART.  Some individuals experience a clinical deterioration marked by severe 
inflammation after initiating cART.  This immune reconstitution inflammatory syndrome 
(IRIS) can occur in patients who have recently started cART and who may have had low 
CD4 counts that put them at risk for a variety of opportunistic infections.  The 9-month 
treatment criterion limited the chances of IRIS being responsible for clinical findings and 
thus ensured more accurate assessment.  Because of the 9-month treatment criterion, a 
number of participants had to be excluded from the follow-up group.  Having larger follow-
up numbers could have produced more significant results in the correlation studies of 
baseline inflammation and cognitive improvement following cART. 
 
The cytokines in this study were measured using antibody microarray assays, which is 
considered a reliable method for analysing profiles of inflammatory markers where 
volumes are limited (Knight et al. 2004).  The majority of studies correlated the results of 
the microarray assays and ELISAs, although the degree of correlation varied widely 
(Elshal and McCoy 2006; Ray et al. 2005; Chen et al. 1999).  Multiplex assays might, 
however, not accurately measure the actual levels of cytokines and significant variations 
have been found between the absolute cytokine concentrations as determined by ELISA 
and the multiplex kits (dupont et al. 2005).  This might have been the case in my study 
where measured concentrations of IL-1β, TNF-α, and IL-10 were generally low.  The multi-
analyte studies were performed by the CPGR laboratory, and performing ELISAs in our 
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own lab might have given better results.  It was, however, not possible to perform ELISAs 
due to cost, time, labour and volume of sample limitations.  Thawing and re-freezing of the 
serum samples could also have affected the results. 
 
Another major limitation of this study was the unavailability of CSF due to the lack of 
approval from the HREC of UCT/GSH for performing lumbar punctures at the time of 
baseline assessment.  As mentioned before, there are sound reasons for measuring 
inflammation in the blood, but CSF might still have provided me with a more accurate 
reflection of brain inflammation.  CSF would also have been useful in excluding latent or 
subclinical CNS infections that might have confounded the diagnostic criteria for HAD.  
The participants did at least have thorough clinical assessments and neuro-imaging at 
baseline that assisted in excluding other potential causes for cognitive impairment.  I think 
it is still worthwhile to examine the more accessible peripheral circulation for potential 
markers of inflammation that might correlate with neuroinflammation and cognitive 
impairment. 
 
An ideal study would involve larger numbers at baseline, and at follow-up.  A lumbar 
puncture should be performed at baseline and CSF cytokine concentrations should be 
related to serum cytokines at baseline.  I would have collected serum for a second blood 
inflammatory profile at the follow-up visit.  A wider range of pro- and anti-inflammatory 
cytokines should perhaps also be assayed at baseline and follow-up.  ELISA technique 
would be used for cytokine assays instead of multi-analyte detection.  Other 
measurements of inflammation such as TNFα receptor and the CD40 Ligand, a 
glycoprotein that has been related to cognitive impairment in HIV, may be more useful (Sui 
et al. 2007; Ryan et al. 2001).  In vivo measurements such as magnetic resonance 
spectroscopy of the brain could also provide more accurate CNS measurements of 
inflammation.  An older group of HIV-positive participants (> 50 years of age) from the 
same population will be included for APOE genotyping and correlation with cognitive 
function. 
 
This study, nevertheless, remains important in that it formed part of the first detailed HAND 
study in South Africa.  I investigated the role of systemic inflammation in HIV-associated 
cognitive impairment.  For the first time in southern Africa we were able to relate peripheral 
inflammatory markers and APOE genotype to cognitive function.   The setting of this study 
in the primary care ARV clinics of Cape Town also made it valuable and generalizable to 
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CHAPTER 7: CONCLUSIONS 
 
This study provided information about young HIV-positive patients in South Africa where 
clade C HIV-1 infection is highly prevalent. 
 
Although no significant correlations were found between systemic inflammation and 
cognitive impairment, further investigation is warranted.  Using alternative cytokine assay 
techniques and a wider variety of cytokines might yield better results.  Finding a potential 
predictor of HIV-associated cognitive impairment in the blood will be paramount in the 
resource limited South African setting. 
 
A high prevalence of the ε4 allele was found in the study population.  Further investigation 
of the role of APOE genotype in HIV-associated cognitive impairment is needed.  This 
might involve the inclusion of older HIV-positive participants as a comparison group. 
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